Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).
A malignant tumor arising from secreting cells of a racemose gland, particularly the salivary glands. Racemose (Latin racemosus, full of clusters) refers, as does acinar (Latin acinus, grape), to small saclike dilatations in various glands. Acinar cell carcinomas are usually well differentiated and account for about 13% of the cancers arising in the parotid gland. Lymph node metastasis occurs in about 16% of cases. Local recurrences and distant metastases many years after treatment are common. This tumor appears in all age groups and is most common in women. (Stedman, 25th ed; Holland et al., Cancer Medicine, 3d ed, p1240; from DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p575)
A greasy substance with a smoky odor and burned taste created by high temperature treatment of BEECH and other WOOD; COAL TAR; or resin of the CREOSOTE BUSH. It contains CRESOLS and POLYCYCLIC AROMATIC HYDROCARBONS which are CARCINOGENS. It has been widely used as wood preservative and in PESTICIDES and had former use medicinally in DISINFECTANTS; LAXATIVES; and DERMATOLOGIC AGENTS.
Small oviparous fishes in the family Cyprinodontidae, usually striped or barred black. They are much used in mosquito control.
Surgical removal of the pancreas. (Dorland, 28th ed)
A true cyst of the PANCREAS, distinguished from the much more common PANCREATIC PSEUDOCYST by possessing a lining of mucous EPITHELIUM. Pancreatic cysts are categorized as congenital, retention, neoplastic, parasitic, enterogenous, or dermoid. Congenital cysts occur more frequently as solitary cysts but may be multiple. Retention cysts are gross enlargements of PANCREATIC DUCTS secondary to ductal obstruction. (From Bockus Gastroenterology, 4th ed, p4145)
Carcinoma that arises from the PANCREATIC DUCTS. It accounts for the majority of cancers derived from the PANCREAS.
A cystic tumor of the ovary, containing thin, clear, yellow serous fluid and varying amounts of solid tissue, with a malignant potential several times greater than that of mucinous cystadenoma (CYSTADENOMA, MUCINOUS). It can be unilocular, parvilocular, or multilocular. It is often bilateral and papillary. The cysts may vary greatly in size. (Dorland, 27th ed; from Hughes, Obstetric-Gynecologic Terminology, 1972)
Conducting a fine needle biopsy with the aid of ENDOSCOPIC ULTRASONOGRAPHY.
An adenocarcinoma producing mucin in significant amounts. (From Dorland, 27th ed)
A nodular organ in the ABDOMEN that contains a mixture of ENDOCRINE GLANDS and EXOCRINE GLANDS. The small endocrine portion consists of the ISLETS OF LANGERHANS secreting a number of hormones into the blood stream. The large exocrine portion (EXOCRINE PANCREAS) is a compound acinar gland that secretes several digestive enzymes into the pancreatic ductal system that empties into the DUODENUM.
Ultrasonography of internal organs using an ultrasound transducer sometimes mounted on a fiberoptic endoscope. In endosonography the transducer converts electronic signals into acoustic pulses or continuous waves and acts also as a receiver to detect reflected pulses from within the organ. An audiovisual-electronic interface converts the detected or processed echo signals, which pass through the electronics of the instrument, into a form that the technologist can evaluate. The procedure should not be confused with ENDOSCOPY which employs a special instrument called an endoscope. The "endo-" of endosonography refers to the examination of tissue within hollow organs, with reference to the usual ultrasonography procedure which is performed externally or transcutaneously.
A benign tumor of the pancreatic ISLET CELLS. Usually it involves the INSULIN-producing PANCREATIC BETA CELLS, as in INSULINOMA, resulting in HYPERINSULINISM.
Ducts that collect PANCREATIC JUICE from the PANCREAS and supply it to the DUODENUM.
An adenocarcinoma containing finger-like processes of vascular connective tissue covered by neoplastic epithelium, projecting into cysts or the cavity of glands or follicles. It occurs most frequently in the ovary and thyroid gland. (Stedman, 25th ed)
A malignant neoplasm characterized by the formation of numerous, irregular, finger-like projections of fibrous stroma that is covered with a surface layer of neoplastic epithelial cells. (Stedman, 25th ed)
A malignant epithelial tumor with a glandular organization.
INFLAMMATION of the PANCREAS. Pancreatitis is classified as acute unless there are computed tomographic or endoscopic retrograde cholangiopancreatographic findings of CHRONIC PANCREATITIS (International Symposium on Acute Pancreatitis, Atlanta, 1992). The two most common forms of acute pancreatitis are ALCOHOLIC PANCREATITIS and gallstone pancreatitis.
Tomography using x-ray transmission and a computer algorithm to reconstruct the image.
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.
Neoplasms containing cyst-like formations or producing mucin or serum.
Tumors or cancer of the SKIN.
Two or more abnormal growths of tissue occurring simultaneously and presumed to be of separate origin. The neoplasms may be histologically the same or different, and may be found in the same or different sites.
Tumors or cancers of the KIDNEY.
Abnormal growths of tissue that follow a previous neoplasm but are not metastases of the latter. The second neoplasm may have the same or different histological type and can occur in the same or different organs as the previous neoplasm but in all cases arises from an independent oncogenic event. The development of the second neoplasm may or may not be related to the treatment for the previous neoplasm since genetic risk or predisposing factors may actually be the cause.
Tumors or cancer of the THYROID GLAND.
Conditions which cause proliferation of hemopoietically active tissue or of tissue which has embryonic hemopoietic potential. They all involve dysregulation of multipotent MYELOID PROGENITOR CELLS, most often caused by a mutation in the JAK2 PROTEIN TYROSINE KINASE.
DNA present in neoplastic tissue.
Tumors or cancer of the LUNG.
Tumors or cancer of the PAROTID GLAND.
A benign neoplasm derived from glandular epithelium, in which cystic accumulations of retained secretions are formed. In some instances, considerable portions of the neoplasm, or even the entire mass, may be cystic. (Stedman, 25th ed)
Neoplasms developing from some structure of the connective and subcutaneous tissue. The concept does not refer to neoplasms located in connective or soft tissue.
Neoplasms associated with a proliferation of a single clone of PLASMA CELLS and characterized by the secretion of PARAPROTEINS.
Tumors or cancer of the APPENDIX.
Tumors or cancer of the LIVER.
A multilocular tumor with mucin secreting epithelium. They are most often found in the ovary, but are also found in the pancreas, appendix, and rarely, retroperitoneal and in the urinary bladder. They are considered to have low-grade malignant potential.
Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.
Tumors or cancer of the ENDOCRINE GLANDS.
Tumors or cancer of the GASTROINTESTINAL TRACT, from the MOUTH to the ANAL CANAL.
Experimentally induced new abnormal growth of TISSUES in animals to provide models for studying human neoplasms.
Neoplasms composed of vascular tissue. This concept does not refer to neoplasms located in blood vessels.
Tumors or cancer of the EYE.
Histochemical localization of immunoreactive substances using labeled antibodies as reagents.
Tumors or cancer of the NOSE.
Tumors or cancer of the SALIVARY GLANDS.
Tumors, cancer or other neoplasms produced by exposure to ionizing or non-ionizing radiation.
Tumors or cancer of the TESTIS. Germ cell tumors (GERMINOMA) of the testis constitute 95% of all testicular neoplasms.
Neoplasms composed of muscle tissue: skeletal, cardiac, or smooth. The concept does not refer to neoplasms located in muscles.
Neoplasms composed of glandular tissue, an aggregation of epithelial cells that elaborate secretions, and of any type of epithelium itself. The concept does not refer to neoplasms located in the various glands or in epithelial tissue.
A malignant cystic or semisolid tumor most often occurring in the ovary. Rarely, one is solid. This tumor may develop from a mucinous cystadenoma, or it may be malignant at the onset. The cysts are lined with tall columnar epithelial cells; in others, the epithelium consists of many layers of cells that have lost normal structure entirely. In the more undifferentiated tumors, one may see sheets and nests of tumor cells that have very little resemblance to the parent structure. (Hughes, Obstetric-Gynecologic Terminology, 1972, p184)
A benign epithelial tumor with a glandular organization.
Neoplasms of whatever cell type or origin, occurring in the extraskeletal connective tissue framework of the body including the organs of locomotion and their various component structures, such as nerves, blood vessels, lymphatics, etc.
Neoplasms located in the blood and blood-forming tissue (the bone marrow and lymphatic tissue). The commonest forms are the various types of LEUKEMIA, of LYMPHOMA, and of the progressive, life-threatening forms of the MYELODYSPLASTIC SYNDROMES.
Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm.
Tumors or cancer of the UTERUS.
Tumors or cancer of the INTESTINES.
Neoplasms composed of sebaceous or sweat gland tissue or tissue of other skin appendages. The concept does not refer to neoplasms located in the sebaceous or sweat glands or in the other skin appendages.
Methods which attempt to express in replicable terms the extent of the neoplasm in the patient.
Neoplasms located in the vasculature system, such as ARTERIES and VEINS. They are differentiated from neoplasms of vascular tissue (NEOPLASMS, VASCULAR TISSUE), such as ANGIOFIBROMA or HEMANGIOMA.
A general term for various neoplastic diseases of the lymphoid tissue.
Tumors or cancer located in bone tissue or specific BONES.
Tumors or cancer of the PALATE, including those of the hard palate, soft palate and UVULA.
Neoplasms composed of more than one type of neoplastic tissue.
Proteins, glycoprotein, or lipoprotein moieties on surfaces of tumor cells that are usually identified by monoclonal antibodies. Many of these are of either embryonic or viral origin.
Tumors or cancer of the MANDIBLE.
A malignant neoplasm derived from glandular epithelium, in which cystic accumulations of retained secretions are formed. The neoplastic cells manifest varying degrees of anaplasia and invasiveness, and local extension and metastases occur. Cystadenocarcinomas develop frequently in the ovaries, where pseudomucinous and serous types are recognized. (Stedman, 25th ed)
Tumors or cancer of the BILE DUCTS.
Ability of neoplasms to infiltrate and actively destroy surrounding tissue.
Tumors or cancer of the THYMUS GLAND.
Tumors or cancer of the SPLEEN.

Rational sequence of tests for pancreatic function. (1/9206)

Of 144 patients with suspected pancreatic disease in whom a 75Se-selenomethionine scan was performed, endoscopic retrograde pancreatography (ERP) was successful in 108 (75%). The final diagnosis is known in 100 patients and has been compared with scan and ERP findings. A normal scan reliably indicated a normal pancreas, but the scan was falsely abnormal in 30%. ERP distinguished between carcinoma and chronic pancreatitis in 84% of cases but was falsely normal in five patients with pancreatic disease. In extrahepatic biliary disease both tests tended to give falsely abnormal results. A sequence of tests to provide a rapid and reliable assessment of pancreatic function should be a radio-isotope scan, followed by ERP if the results of the scan are abnormal, and a Lundh test if the scan is abnormal but the findings on ERP are normal.  (+info)

Diphtheria toxin effects on human cells in tissue culture. (2/9206)

HeLa cells exposed to a single sublethal concentration of diphtheria toxin were found to have diminished sensitivity when subsequently reexposed to the toxin. Three cells strains exhibiting toxin resistance were developed. In the cells that had previously been exposed to toxin at 0.015 mug/ml, 50% inhibition of protein synthesis required a toxin concentration of 0.3 mug/ml, which is more than 10 times that required in normal HeLa cells. There appears to be a threshold level of diphtheria toxin action. Concentrations of toxin greater than that required for 50% inhibition of protein synthesis (0.01 mug/ml) are associated with cytotoxicity, whereas those below this concentration may not be lethal. Several established human cell lines of both normal and neoplastic origin were tested for their sensitivity to the effects of the toxin. No special sensitivity was observed with the cells of tumor origin. Fifty % inhibition of protein synthesis of HeLa cells was achieved with diphtheria toxin (0.01 mug/ml) as compared to the normal human cell lines tested (0.03 and 0.5 mug/ml) and a cell line derived from a human pancreatic adenocarcinoma (0.2 mug/ml). A human breast carcinoma cell line showed a maximum of 45% inhibition of protein synthesis. This required a diphtheria toxin concentration of 5 mug/ml. These results suggest that different human cell lines show wide variation in their sensitivity to the toxin.  (+info)

Expression and differential regulation of connective tissue growth factor in pancreatic cancer cells. (3/9206)

CTGF is an immediate early growth responsive gene that has been shown to be a downstream mediator of TGFbeta actions in fibroblasts and vascular endothelial cells. In the present study hCTGF was isolated as immediate early target gene of EGF/TGFalpha in human pancreatic cancer cells by suppression hybridization. CTGF transcripts were found in 13/15 pancreatic cancer cell lines incubated with 10% serum. In 3/7 pancreatic cancer cell lines EGF/TGFalpha induced a significant rise of CTGF transcript levels peaking 1-2 h after the start of treatment. TGFbeta increased CTGF transcript levels in 2/7 pancreatic cancer cell lines after 4 h of treatment and this elevation was sustained after 24 h. Only treatment with TGFbeta was accompanied by a parallel induction of collagen type I transcription. 15/19 human pancreatic cancer tissues were shown to overexpress high levels of CTGF transcripts. CTGF transcript levels in pancreatic cancer tissues and nude mouse xenograft tumors showed a good correlation to the degree of fibrosis. In situ hybridization and the nude mouse experiments revealed that in pancreatic cancer tissues, fibroblasts are the predominant site of CTGF transcription, whereas the tumor cells appear to contribute to a lesser extent. We conclude that CTGF may be of paramount importance for the development of the characteristic desmoplastic reaction in pancreatic cancer tissues.  (+info)

Detection of liver metastases from pancreatic cancer using FDG PET. (4/9206)

We evaluated the potential of the glucose analog [18F]fluorodeoxyglucose (FDG) as a PET tracer for the hepatic staging in 168 patients designated for resective pancreatic surgery. METHODS: Metastatic liver disease was confirmed or excluded during surgery or with CT follow-up for at least 6 mo. Proven metastases were then retrospectively identified on preoperative CT (gold standard). Hepatic PET scans of all patients were interpreted blindly. Any focal FDG uptake was considered malignant. Both proven hepatic metastases and suspicious hepatic PET lesions were then compared, lesion by lesion, with CT. Standardized uptake values (SUV) and tumor-to-liver ratios (T/L) were determined for the most intense lesion of each patient. RESULTS: Sensitivity of FDG PET was 68% (15 of 22 patients). The lesion detection rate was 97% (28 of 29 metastases) for lesions >1 cm and 43% (16 of 37 metastases) for lesions < or = 1 cm. Specificity was 95% (138 of 146 patients). Six of eight patients with false-positive results had marked intrahepatic cholestasis (versus 3 of 15 patients with true-positive lesions), one had an infrahepatic abscess and one had a right basal pulmonary metastasis. The SUV and T/L were 4.6+/-1.4 and 2.3+/-1.1, respectively, for malignant lesions and 4.1+/-1.5 and 1.9+/-0.3, respectively, for false-positive lesions and therefore are of limited value. CONCLUSION: FDG PET provides reliable hepatic staging for lesions >1 cm. False-positive results are associated with the presence of marked intrahepatic cholestasis. For lesions < or = 1 cm, FDG PET can define malignancy in 43% of suspicious CT lesions in the absence of dilated bile ducts.  (+info)

Intensive weekly chemotherapy is not effective in advanced pancreatic cancer patients: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). (5/9206)

Twenty-two patients, with locally advanced unresectable and/or metastatic pancreatic carcinoma, received weekly administration of cisplatin 40 mg m(-2), 5-fluorouracil 500 mg m(-2), epidoxorubicin 35 mg m(-2), 6S stereoisomer of leucovorin 250 mg m(-2) and glutathione 1.5 mg m(-2), supported by a daily administration of lenograstim at a dose of 5 microg kg(-1). Nineteen patients were men and three were women. Median age was 63 years (range 47-70). At study entry, pain was present in 15 out of 22 patients (68%) with a mean value of Scott-Huskisson scale of 27.6+/-23.8, whereas a weight loss >10% was present in 15 patients. After eight weekly treatments, three partial responses were achieved for a response rate of 13% (95% CI 0-26%), five patients had stable disease and 14 progressed on therapy. Pain was present in 9 out of 22 patients (40%) with a mean value of Scott-Huskisson scale of 12.3+/-18.4. Eight patients (36%) (three partial response and five stable disease) had a positive weight change. Toxicity was mild: WHO grade III or IV toxicity was recorded in terms of anaemia in 7 out of 188 cycles (3.7%), of neutropenia in 9 out of 188 cycles (4.7%) and of thrombocytopenia in 3 out of 188 cycles (1.5%). Median survival of all patients was 6 months. The outcome of this intensive chemotherapy regimen does not support its use in pancreatic cancer.  (+info)

Treatment of advanced pancreatic cancer with the long-acting somatostatin analogue lanreotide: in vitro and in vivo results. (6/9206)

Fourteen patients with metastatic pancreatic adenocarcinoma were treated with the long-acting somatostatin (SST) analogue lanreotide. No objective response was obtained, and the median survival was 4 months (range 1.8-7 months). Pancreatic cancer could not be visualized by means of SST-receptor (R) scintigraphy in our patients. In vitro data also demonstrated absence of SSTR2 expression, suggesting pancreatic cancer not to be a potential target for treatment with SST analogues.  (+info)

Gallstones, cholecystectomy and risk of cancers of the liver, biliary tract and pancreas. (7/9206)

To examine the association between gallstones and cholecystectomy, we conducted a nationwide population-based cohort study in Denmark. Patients with a discharge diagnosis of gallstones from 1977 to 1989 were identified from the Danish National Registry of Patients and followed up for cancer occurrence until death or the end of 1993 by record linkage to the Danish Cancer Registry. Included in the cohort were 60 176 patients, with 471 450 person-years of follow-up. Cancer risks were estimated by standardized incidence ratios (SIRs) and 95% confidence intervals (CIs) stratified by years of follow-up and by cholecystectomy status. Among patients without cholecystectomy, the risks at 5 or more years of follow-up were significantly elevated for cancers of liver (SIR = 2.0, CI = 1.2-3.1) and gallbladder (SIR = 2.7, CI = 1.5-4.4) and near unity for cancers of extrahepatic bile duct (SIR = 1.1), ampulla of Vater (SIR = 1.0) and pancreas (SIR = 1.1). The excess risk of liver cancer was seen only among patients with a history of hepatic disease. Among cholecystectomy patients, the risks at 5 or more years of follow-up declined for cancers of liver (SIR = 1.1) and extrahepatic bile duct (SIR = 0.7), but were elevated for cancers of ampulla of Vater (SIR = 2.0, CI = 1.0-3.7) and pancreas (SIR = 1.3, CI = 1.1-1.6). These findings confirm that gallstone disease increases the risk of gallbladder cancer, whereas cholecystectomy appears to increase the risk of cancers of ampulla of Vater and pancreas. Further research is needed to clarify the carcinogenic risks associated with gallstones and cholecystectomy and to define the mechanisms involved.  (+info)

Mutations and allelic deletions of the MEN1 gene are associated with a subset of sporadic endocrine pancreatic and neuroendocrine tumors and not restricted to foregut neoplasms. (8/9206)

Endocrine pancreatic tumors (EPT) and neuroendocrine tumors (NET) occur sporadically and rarely in association with multiple endocrine neoplasia type 1 (MEN1). We analyzed the frequency of allelic deletions and mutations of the recently identified MEN1 gene in 53 sporadic tumors including 30 EPT and 23 NET (carcinoids) of different locations and types. Allelic deletion of the MEN1 locus was identified in 18/49 (36.7%) tumors (13/30, 43.3% in EPT and 5/19, 26.3% in NET) and mutations of the MEN1 gene were present in 8/52 (15.3%) tumors (4/30 (13.3%) EPT and 4/22 (18.1%) NET). The somatic mutations were clustered in the 5' region of the coding sequence and most frequently encompassed missense mutations. All tumors with mutations exhibited a loss of the other allele and a wild-type sequence of the MEN1 gene in nontumorous DNA. In one additional patient with a NET of the lung and no clinical signs or history of MEN1, a 5178-9G-->A splice donor site mutation in intron 4 was identified in both the tumor and blood DNA, indicating the presence of a thus far unknown MEN1 syndrome. In most tumor groups the frequency of allelic deletions at 11q13 was 2 to 3 times higher than the frequency of identified MEN1 gene mutations. Some tumor types, including rare forms of EPT and NET of the duodenum and small intestine, exhibited mutations more frequently than other types. Furthermore, somatic mutations were not restricted to foregut tumors but were also detectable in a midgut tumor (15.2% versus 16.6%). Our data indicate that somatic MEN1 gene mutations contribute to a subset of sporadic EPT and NET, including midgut tumors. Because the frequency of mutations varies significantly among the investigated tumor subgroups and allelic deletions are 2 to 3 times more frequently observed, factors other than MEN1 gene inactivation, including other tumor-suppressor genes on 11q13, may also be involved in the tumorigenesis of these neoplasms.  (+info)

Searching for the cost of Pancreatic Cancer Treatment in Kolkata? Contact Lyfboat to Get an Expert Second Opinion and Personalised Quote for Pancreatic Cancer Treatment from the best Pancreatic Cancer Treatment hospitals in Kolkata. We enable patients to connect, communicate and find quality healthcare for Pancreatic Cancer Treatment in Kolkata.
TY - JOUR. T1 - Characterization of a newly established human pancreatic carcinoma cell line, UK Pan-1. AU - Fralix, Kimberly D.. AU - Ahmed, Mansoor M.. AU - Mattingly, Cynthia. AU - Swiderski, Carol. AU - McGrath, Patrick C.. AU - Venkatasubbarao, Kolaparthi. AU - Kamada, Nanao. AU - Mohiuddin, Mohammed. AU - Strodel, William E.. AU - Freeman, James W.. PY - 2000/5/1. Y1 - 2000/5/1. N2 - BACKGROUND. A highly tumorigenic cell line designated as UK Pan-1 was established in a surgically removed human pancreatic adenocarcinoma and characterized as having many of the genotypic and phenotypic alterations commonly found in pancreatic tumors. METHODS. The cell line was characterized by its morphology, growth rate in monolayer culture and soft agar, tumorigenicity in nude mice, and chromosomal analysis. Furthermore, the status of p53, Ki-ras mutation and transforming growth factor (TGF)-β receptor expression were determined. The characteristics of UK Pan-1 were compared with those of other commonly ...
My husband's pancreatic cancer treatment. Our doctor, David Fogelman, M.D., explained Ken's pancreatic cancer treatment options using chemotherapy.
Abstract Background Pancreatic carcinoma usually is a fatal disease with no cure, mainly due to its invasion and metastasis prior to diagnosis. We analyzed the gene expression profiles of paired primary pancreatic tumors and metastatic lesions from Ela-c-myc transgenic mice in order to identify genes that may be involved in the pancreatic cancer progression. Differentially expressed selected genes were verified by semi-quantitative and quantitative RT-PCR. To further evaluate the relevance of some of the selected differentially expressed genes, we investigated their expression pattern in human pancreatic cancer cell lines with high and low metastatic potentials. Results Data indicate that genes involved in posttranscriptional regulation were a major functional category of upregulated genes in both primary pancreatic tumors (PT) and liver metastatic lesions (LM) compared to normal pancreas (NP). In particular, differential expression for splicing factors, RNA binding/pre-mRNA processing factors and
Pancreatic cancer treatment with whipple procedure (pancreaticoduodenectomy) (costs for program #146009) ✔ University Hospital of the Ludwig-Maximilians-University Munich ✔ Department of General Surgery, Traumatology and Reconstructive Surgery ✔ BookingHealth.com
Pancreatic cancer treatment with whipple procedure (pancreaticoduodenectomy) (costs for program #158863) ✔ University Hospital Bonn ✔ Department of General, Visceral, Thoracic and Vascular Surgery ✔ BookingHealth.com
https://www.nature.com/articles/s41598-020-65804-5. San Diego, California., June 8, 2020 - Researchers at the Human BioMolecular Research Institute and ChemRegen, Inc., have reported on a small molecule p53 Activator Wnt Inhibitor-2 (PAWI-2) that potently inhibits human pancreatic cancer stem cells. Writing June 8, 2020 in the journal Scientific Reports, the team describes how they tested PAWI-2, a synthetic, drug-like compound that can be used to decrease human pancreatic cancer. Pancreatic cancer remains a major health problem in the United States and soon will be the second most common cause of mortality due to cancer. A majority of pancreatic cancer patients are often resistant to clinical therapies. Thus, it remains a challenge to develop an efficacious clinically useful pancreatic cancer therapy said Jiongjia Cheng, Ph.D., lead author of the study. Using a non-toxic small molecule to decrease pancreatic cancer is very attractive.. Medicinal chemistry leads to safe anti-cancer ...
MedStar Montgomery Medical Center offers a wide array of advanced Pancreatic Cancer treatments for both complex and common Pancreatic Cancer types.
TY - JOUR. T1 - KAI1 expression is up-regulated in early pancreatic cancer and decreased in the presence of metastases. AU - Guo, Xiaozhong. AU - Friess, Helmut. AU - Graber, Hans U.. AU - Kashiwagi, Mikiya. AU - Zimmermann, Arthur. AU - Korc, Murray. AU - Büchler, Markus W.. PY - 1996/11/1. Y1 - 1996/11/1. N2 - KAI1 is a metastasis suppressor gene for prostate cancer that is located on chromosome 11p11.2-13. Using Northern blot analysis and in situ hybridization, we studied expression of KAI1 mRNA in specimens from 14 normal pancreases and 27 primary pancreatic cancers, and then correlated the findings with the clinical and histopathological parameters of the patients. Northern blot analysis showed increased steady-state levels of KAI1 mRNA expression in 24 of 27 (89%) pancreatic cancer samples. In situ hybridization showed enhanced KAI1 mRNA levels in the pancreatic cancer cells in 82% cancer tissues. The stroma surrounding the cancer mass and normal pancreatic tissue adjacent to the cancer ...
28+ Treatment In India - Ivf In Delhi Fertility Treatment In India, Recent Advances In Treatment Of Malaria, Treatment For Coronary Artery Disease In India Expert Cardiac S, Cancer Treatment In India Advantages, Panchakarma Treatment In India Pachakarma Kerala Kerala Tourism A, Pancreatic Cancer Treatment An Effective Remedy To Curepancreatic Cancer Tourism City, Affordable Gums Periodontal Treatment In India, Breast Cancer Treatment In India | Www.velkommen.org
Pancreatic cancer is known to be the deadliest of all common cancers. Despite all efforts in pancreatic cancer treatment, the five-year survival rates at diagnosis over the past 20 years have only increased from 5% to 8%. Assuming that pancreatic cancer is going to become the second most frequent cause of cancer related death in the next 20 years, we are all encouraged to treat patients in clinical trials to gain improvements in this devastating disease. Areas covered: This review will provide a summary of pancreatic cancer treatment over the last 20 years, starting with the pivotal study in 1997 which showed the superiority of gemcitabine over 5-FU in advanced pancreatic cancer and is marked as the beginning of a new era in pancreatic cancer treatment ...
Pancreatic cancer treatment side effects & their severity can vary greatly. Learn about potential side effects of the most common treatment options.
The Hoag-USC team then carefully tailors a personalized Pancreatic Cancer treatment plan to effectively achieve the best possible outcome for the patient.
➤ Pancreatic cancer treatment in clinics of Anyang, ➤ 16 clinics, Addresses, $ Prices for treatments and diagnostics, ☺ 43 reviews, ✎ Make an appointment, ✉ 3,469 patients are sent for treatment
The global pancreatic cancer treatment market is expected to reach USD 4.2 billion in 2025, according to a new report by Grand View Research, Inc. Increasi
Despite intense efforts over the past 30 years, human pancreatic β cell lines have not been available. Here, we describe a robust technology for producing a functional human β cell line using targeted oncogenesis in human fetal tissue. Human fetal pancreatic buds were transduced with a lentiviral ve …
1240 The epidermal growth factor receptor (EGFR) is overexpressed in up to 60% of pancreatic cancer specimens. Recently, erlotinib (a small-molecule tyrosine kinase inhibitor, TKI) was approved for pancreatic cancer treatment. There is an association between TKI response in non-small cell lung cancer (NSCLC) and specific activating mutations in the EGFR tyrosine kinase (TK) domain. The applicability of this paradigm in pancreatic cancer was analyzed by evaluating the presence of activating EGFR TK mutations and EGFR pathway activation in a large cohort of pancreatic adenocarcinoma patients. Pancreatic adenocarcinoma is characterized by an exuberant desmoplastic reaction, masking precise analysis of tumor cells. State-of-the-art laser capture microdissection (LCM) allowed us to selectively isolate pancreatic ductal adenocarcinoma cells from their surrounding stromal elements. DNA, protein, and mRNA were extracted from 30 human frozen pancreatic cancer specimens following LCM of tissue sections ...
Occupational exposure to hydrocarbon solvents has been found to be associated with an increased risk of exocrine pancreatic cancer (EPC), the human tumor with the highest prevalence of K-ras mutations. Ras genes are critical DNA targets for chemical carcinogens. We analysed the relationship between past occupational exposure to hydrocarbon solvents and mutations in codon 12 of the K-ras gene in 107 incident cases of EPC. Information on occupational factors and life-style was obtained from personal interviews conducted during hospital stay. Occupational exposure to hydrocarbon solvents (aliphatic, aromatic, chlorinated, benzene, other organic solvents) was examined using two methods: expert assessment and the Finnish job-exposure matrix (Finjem). Exposure among K-ras mutated EPC cases (n = 83) was compared with that of K-ras wild-type EPC cases (n = 24). An association between K-ras mutations and solvent exposure was observed with Finjem but barely so with the expert assessment. Over 7-fold ...
TY - JOUR. T1 - Stable transduction of human pancreatic adenocarcinoma cells, rat fibroblasts, and bone marrow-derived stem cells with recombinant adeno- associated virus containing the rat preproisulin II gene. AU - Bochan, M. R.. AU - Sidner, R. A.. AU - Shah, R.. AU - Cummings, O. W.. AU - Goheen, M.. AU - Jindal, R. M.. PY - 1998/1/1. Y1 - 1998/1/1. UR - http://www.scopus.com/inward/record.url?scp=0031978015&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=0031978015&partnerID=8YFLogxK. U2 - 10.1016/S0041-1345(97)01353-5. DO - 10.1016/S0041-1345(97)01353-5. M3 - Article. C2 - 9532125. AN - SCOPUS:0031978015. VL - 30. SP - 453. EP - 454. JO - Transplantation Proceedings. JF - Transplantation Proceedings. SN - 0041-1345. IS - 2. ER - ...
INTRODUCTION: Until now, studies examining the relationship between socioeconomic status and pancreatic cancer incidence have been inconclusive.. AIM: To prospectively investigate to what extent pancreatic cancer incidence varies according to educational level within the European Prospective Investigation into Cancer and Nutrition (EPIC) study.. METHODS: In the EPIC study, socioeconomic status at baseline was measured using the highest level of education attained. Hazard ratios by educational level and a summary index, the relative indices of inequality (RII), were estimated using Cox regression models stratified by age, gender, and center and adjusted for known risk factors. In addition, we conducted separate analyses by age, gender and geographical region.. RESULTS: Within the source population of 407, 944 individuals at baseline, 490 first incident primary pancreatic adenocarcinoma cases were identified in 9 European countries. The crude difference in risk of pancreatic cancer according to ...
ROCKVILLE, Md., Jan. 20, 2017 (GLOBE NEWSWIRE) - Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing next generation targeted therapeutics for the treatment of cancer, today announced an update on the safety and efficacy of RX-3117 in an ongoing Phase IIa clinical trial in metastatic pancreatic cancer at the American Society for Clinical Oncology (ASCO) 2017 Gastrointestinal Cancer Symposium in San Francisco California.. The data on progression free survival in metastatic pancreatic cancer patients treated with RX-3117 is very encouraging with 20% of patients exhibiting progression free survival of greater than 5.6 months (with one patient having progression free survival of 7.2 months). A majority of the patients enrolled in the trial have already failed 3 or more prior cancer therapies. Current options for these patients are usually limited to palliative or best supportive care; there are no drugs approved for metastatic pancreatic cancer ...
MANHATTAN BEACH, Calif., Nov. 9, 2012 /PRNewswire/ -- The Pancreatic Cancer Action Network is pleased to announce Abraxane® extends survival for patients with advanced pancreatic cancer. According to Celgene Corporation, Abraxane in combination with gemcitabine when given to advanced pancreatic cancer patients who had not received previous treatment demonstrated a statistically significant improvement in overall survival compared to patients receiving gemcitabine alone. (Logo: http://photos.prnewswire.com/prnh/20111004/LA79914LOGO). The phase III study included 861 metastatic pancreatic cancer patients from around the world. Full results from the clinical trial will be presented at the American Society of Clinical Oncologys 2013 Gastrointestinal Cancers Symposium being held in January. Historically, few effective treatment options for pancreatic cancer have existed. We are thrilled to have a new treatment option for patients with advanced pancreatic cancer. We look forward to learning more ...
Pancreatic cancer is considered the third most deadly form of the disease and leads to a great deal of mortality annually. Pancreatic cancer is not easy to detect owing to where the organ is located. Another reason that makes pancreatic cancer deadly is that it can become resistant to chemotherapy. One of the ways the treatment of pancreatic cancer can be more efficient is the development of a drug that can prevent it from becoming treatment resistant.. In August 2018, Aretha Franklin lost the fight to pancreatic cancer. Other prominent figures that have died from pancreatic cancer include Steve Jobs, Patrick Swayze, Joan Crawford, and Luciano Pavarotti.. This form of cancer is mostly diagnosed at a late stage and chemotherapy will cease to have an effect on the tumors. A combination of early diagnosis and preventing the tumors from becoming resistant to treatment can be a key to extending the life of suffers. According to researchers, cracking this code can extend the life of diagnosed patients ...
Introduction. Solid pseudopapillary neoplasm (SPN) of the pancreas is rare, accounting for 2-3 % of primary pancreatic tumours (1). It was first described by Frantz in 1959 and has since then been referred to as: solid and cystic tumour, solid and papillary neoplasm, Frantzs tumour, papillary-cystic neoplasm and papillary epithelial neoplasm. It was finally defined by the World Health Organization (WHO) in 2000 as a solid pseudopapillary neoplasm of the pancreas (2). SPN is considered a low malignant potential neoplasm, due to its benign morphology and the fact that it rarely metastasizes (3). Even though pancreatic tumours generally have bad prognosis, SPN shows good prognosis, which makes the disease entity unique in this disease group. To predict malignant behavior of SPN, several morphological criteria are needed (angioinvasion, invasion to surrounding tissue or unequivocal perineural invasion) and if present, the tumour should be designated as solid pseudopapillary carcinoma (SPC) (4). We ...
There has been a long standing interest in the identification of medicinal plants and derived natural products for developing cancer therapeutics. Our study focuses upon pancreatic cancer, due to its high mortality rate, that is attributed in part to the lack of an effective chemotherapeutic agent. Previous reports on the use of medicinal plant extracts either alone or alongside conventional anticancer agents in the treatment of this cancer have shown promising results. This work aims to investigate the therapeutic properties of a library of medicinal plants from Bangladesh. 56 extracts of 44 unique medicinal plants were studied. The extracts were screened for cytotoxicity against the pancreatic adenocarcinoma cell line Panc-1, using a label-free biosensor assay. The top cytotoxic extracts identified in this screen were tested on two additional pancreatic cancer cell lines (Mia-Paca2 and Capan-1) and a fibroblast cell line (Hs68) using an MTT proliferation assay. Finally, one of the most promising
Many versions of the free Acrobat Reader do not allow Save. You must instead save the PDF from the CG&D Online page you downloaded it from. PC users: Right-click on the Download link and choose the option that says something like Save Link As.... Mac users should hold the mouse button down on the link to get these same options. ...
Pancreatic cancer has long carried poor prognosis. The development of new therapeutic approaches is particularly urgent. Inactivation of the tumor-suppressor gene p16(INK4a/CDKN2), a specific inhibitor of the cyclin-dependent kinases CDK4 and CDK6, is the most common genetic alteration in human pancreatic cancer, making it an ideal target for gene replacement. Here we transfected tumor cells using a recombinant adenovirus containing the wt-p16 cDNA (Ad5RSV-p16). The overexpression of p16 decreased cell proliferation in all four human pancreatic tumor cell lines (NP-9, NP-18, NP-29, and NP-31). However, G1 arrest and senescence were observed in only three. In contrast, the fourth (NP-18) showed a significant increase in apoptosis. This differential behavior may be related to the differences found in the expression level of E2F-1. Experiments on subcutaneous pancreatic xenografts demonstrated the effectiveness of p16 in the inhibition of pancreatic tumor growth in vivo. Taken together, our results ...
Evidence of a protective effect of several antioxidants and other nutrients on pancreatic cancer risk is inconsistent. The aim of this study was to investigate the association for prediagnostic plasma levels of carotenoids, vitamin C, retinol and tocopherols with risk of pancreatic cancer in a case-control study nested within the ... read more European Prospective Investigation into Cancer and Nutrition (EPIC). 446 incident exocrine pancreatic cancer cases were matched to 446 controls by age at blood collection, study center, sex, date and time of blood collection, fasting status and hormone use. Plasma carotenoids (- and -carotene, lycopene, -cryptoxanthin, canthaxanthin, zeaxanthin and lutein), - and -tocopherol and retinol were measured by reverse phase high-performance liquid chromatography and plasma vitamin C by a colorimetric assay. Incidence rate ratios (IRRs) with 95% confidence intervals (95%CIs) for pancreatic cancer risk were estimated using a conditional logistic regression ...
TY - JOUR. T1 - A phase i study of IMP321 and gemcitabine as the front-line therapy in patients with advanced pancreatic adenocarcinoma. AU - Wang-Gillam, Andrea. AU - Plambeck-Suess, Stacey. AU - Goedegebuure, Peter. AU - Simon, Peter O.. AU - Mitchem, Jonathan B.. AU - Hornick, John R.. AU - Sorscher, Steven. AU - Picus, Joel. AU - Suresh, Rama. AU - Lockhart, Albert. AU - Tan, Benjamin. AU - Hawkins, Williams G.. PY - 2013/6/1. Y1 - 2013/6/1. N2 - Purpose This phase I study was conducted to determine the safety profile and maximum tolerated dose (MTD) of IMP321, a soluble lymphocyte activation gene-3 (LAG-3) Ig fusion protein and MHC Class II agonist, combined with gemcitabine in patients with advanced pancreatic adenocarcinoma. Patients and methods Patients with advanced pancreatic adenocarcinoma were treated with gemcitabine (1,000 mg/m2)(level 1), gemcitabine (1,000 mg/m 2) plus IMP 321 at 0.5 mg (level 2) and 2.0 mg (level 3), respectively. Safety, toxicity, and immunological markers at ...
To address the role of β(1) integrins in pancreatic cancer progression, we stably knocked down β(1) integrin subunit expression in human FG-RFP pancreatic cancer cells using lentiviral-based RNA interference. We then examined the effects of β(1) integrin subunit knockdown on pancreatic cancer cell adhesion, migration and proliferation on tumor microenvironment-specific extracellular matrix proteins in vitro and on tumor progression in vivo using a clinically relevant fluorescent orthotopic mouse model of pancreatic cancer. Knockdown of the β(1) integrin subunit inhibited cell adhesion, migration and proliferation on types I and IV collagen, fibronectin and laminin in vitro. In vivo, knockdown of the β(1) integrin subunit reduced primary tumor growth by 50% and completely inhibited spontaneously occurring metastasis. These observations indicate a critical role for the β(1) integrin subunit in pancreatic cancer progression and metastasis in particular. Our results suggest the β(1) integrin
CCL Dec - Onivyde Combination Boosts OS in Post-Gemcitabine Pancreatic Cancer Patients - Onivyde Combination Boosts OS in Post-Gemcitabine Pancreatic Cancer Patients   A phase III study of Onivyde (irinotecan liposome injection), in combination with fluorouracil and leucovorin, demonstrated improvements in median overall survival in post-gemcitabine metastatic pancreatic cancer patients. The study, NAPOLI-1, was the basis of approval by the FDA in this indication, and the results were recently published in The Lancet.
TY - JOUR. T1 - Phase II trial of salvage therapy with trabectedin in metastatic pancreatic adenocarcinoma. AU - Belli, Carmen. AU - Piemonti, Lorenzo. AU - DIncalci, Maurizio. AU - Zucchetti, Massimo. AU - Porcu, Luca. AU - Cappio, S.. AU - Doglioni, Claudio. AU - Allavena, Paola. AU - Ceraulo, D.. AU - Maggiora, Paola. AU - Dugnani, Erica. AU - Cangi, Mariagiulia. AU - Garassini, Greta. AU - Reni, Michele. PY - 2016/3/1. Y1 - 2016/3/1. N2 - Purpose: No standard salvage chemotherapy has been identified for metastatic pancreatic adenocarcinoma (mPA), and there is an urgent need for active agents against this disease. This phase II trial explored the activity of trabectedin in mPA progressing after gemcitabine-based first-line chemotherapy. Methods: Patients with gemcitabine-resistant disease received trabectedin 1.3 mg/m2 as a 3-h intravenous continuous infusion every 3 weeks until disease progression or unacceptable toxicity or for a maximum of 6 months. The primary endpoint was ...
Acquired 5-Fluorouracil Resistance in Human Pancreatic Carcinoma Cells. A Paradigm for Chemoresistance Mechanisms in Pancreatic Cancer
The role of tuberous sclerosis complex (TSC) in the pathogenesis of pancreatic cancers remains largely unknown. The present study shows that neurogenin 3 directed Cre deletion of Tsc1 gene induces the development of pancreatic acinar carcinoma. By cross-breeding the Neurog3-cre mice with Tsc1(loxp/loxp) mice, we generated the Neurog3-Tsc1-/- transgenic mice in which Tsc1 gene is deleted and mTOR signaling activated in the pancreatic progenitor cells. All Neurog3-Tsc1-/- mice developed notable adenocarcinoma-like lesions in pancreas starting from the age of 100 days old. The tumor lesions are composed of cells with morphological and molecular resemblance to acinar cells. Metastasis of neoplasm to liver and lung was detected in 5% of animals. Inhibition of mTOR signaling by rapamycin significantly attenuated the growth of the neoplasm. Relapse of the neoplasm occurred within 14 days upon cessation of rapamycin treatment. Our studies indicate that activation of mTOR signaling in the pancreatic ...
Pancreatic cancer tissues and cell lines. Sixteen human pancreatic cancer cell lines were used in this study: A818.4, AsPc-1, CFPAC-1, FA6, Hs766T, MDAPanc-3, MiaPaCa-2, PANC-1, PaTu-I, RWP-1, Suit-2, and T3M4 were obtained from Cancer Research UK cell production services. PK1, PK9, and PK59 were established and maintained at Tohoku University (20). All cell lines were kept in a humidified incubator at 37°C with 5% CO2 and cultured in E4 complete medium, supplemented with 10% fetal bovine serum, penicillin (0.1 μg/mL), and streptomycin (100 units/mL). The human pancreatic ductal epithelial cell line HPDE was a kind gift from Dr. Ming-Sound Tsao (University of Toronto, Canada) and was grown in keratinocyte medium as described before (21).. Pancreatic cancer tissues were obtained from the Human Biomaterials Resource Centre (Hammersmith Hospital, London, United Kingdom) and Tohoku University Hospital (Sendai, Japan) with full ethical approval from the host institutions. All tissues used were ...
By blocking production of GM-CSF in pancreatic cancer cells, the researchers found that they were able to disrupt accumulation of myeloid-derived suppressor cells, liberating the tumor-killing immune response. Our study suggests a therapeutic strategy for harnessing the anti-tumor potential of the immune system, Dr. Bar-Sagi explained. Our findings should be applicable to a significant proportion of human pancreatic cancer cases, as the vast majority of human pancreatic cancer samples that we tested express the GM-CSF protein prominently, Dr. Bar-Sagi added. The researchers are hopeful that their findings will open new doors in therapeutic research, eventually leading to new drug therapies that block the production or function of the GM-CSF protein to allow anti-tumor immune cells to attack the cancer cells and halt tumor development. Although the study focuses on pancreatic cancer, KRAS mutations are prevalent in a number of other cancers, including colon and lung cancer. From a research ...
The identification of circulating tumor antigens or their related autoantibodies provides a means for early cancer diagnosis as well as leads for therapy. We have used a proteomic approach to identify proteins that commonly induce a humoral response in pancreatic cancer. Aliquots of solubilized proteins from a pancreatic cancer cell line (Panc-1) were subjected to two-dimensional PAGE, followed by Western blot analysis in which sera of individual patients were tested for primary antibodies. Sera from 36 newly diagnosed patients with pancreatic cancer, 18 patients with chronic pancreatitis, 33 patients with other cancers, and 15 healthy subjects were analyzed. Autoantibodies were detected against either one or two calreticulin isoforms identified by mass spectrometry in sera from 21 of 36 patients with pancreatic cancer. One of 18 chronic pancreatitis patients and 1 of 15 healthy controls demonstrated autoantibodies to calreticulin isoform 1; none demonstrated autoantibodies to isoform 2. None of ...
TY - JOUR. T1 - Inhibition of constitutive NF-κB activity by IκBαM suppresses tumorigenesis. AU - Fujioka, Shuichi. AU - Sclabas, Guido M.. AU - Schmidt, Christian. AU - Niu, Jiangong. AU - Frederick, Wayne A.. AU - Dong, Qiang G.. AU - Abbruzzese, James L.. AU - Evans, Douglas B.. AU - Baker, Cheryl. AU - Chiao, Paul J.. PY - 2003/3/6. Y1 - 2003/3/6. N2 - We have demonstrated that nuclear factor-κB (NF-κB) is constitutively activated in human pancreatic adenocarcinoma and human pancreatic cancer cell lines but not in normal pancreatic tissues or in immortalized, nontumorigenic pancreatic epithelial cells, suggesting that NF-κB plays a critical role in the development of pancreatic adenocarcinoma. To elucidate the role of constitutive NF-κB activity in human pancreatic cancer cells, we generated pancreatic tumor cell lines that express a phosphorylation defective IκBα (S32, 36A) (IκBαM) that blocks NF-κB activity. In this study, we showed that inhibiting constitutive NF-κB activity ...
TY - JOUR. T1 - Immune infiltrates as predictive markers of survival in pancreatic cancer patients. AU - Protti, Maria Pia. AU - De Monte, Lucia. PY - 2013. Y1 - 2013. N2 - Pancreatic cancer is a devastating disease with dismal prognosis. The tumor microenvironment is composed by multiple cell types, molecular factors, and extracellular matrix forming a strong desmoplastic reaction, which is a hallmark of the disease. A complex cross-talk between tumor cells and the stroma exists with reciprocal influence that dictates tumor progression and ultimately the clinical outcome. In this context, tumor infiltrating immune cells through secretion of chemokine and cytokines exert an important regulatory role. Here we review the correlation between the immune infiltrates, evaluated on tumor samples of pancreatic cancer patients underwent surgical resection, and disease free and/or overall survival after surgery. Specifically, we focus on tumor infiltrating lymphocytes (TILs), mast cells (MCs) and ...
Physical exams mainly focus on the abdomen to check for any masses or fluid buildup, which could indicate pancreatic cancer. Pancreatic cancer can also spread to lymph nodes; the lymph nodes will be looked at carefully for swelling during a physical examination.. Imaging tests use x-rays, magnets, sound waves, or radioactive chemicals to produce pictures of the inside of the body. For pancreatic cancer, these will include computed tomography (CT) scans, magnetic resonance imaging (MRI) scans, somatostatin receptor scintigraphy, positron emission tomography (PET) scans, endoscopic ultrasounds, and angiography.. Blood tests for pancreatic cancer are used to make diagnoses and determine a patients treatment options. These tests may include a CA 19-9 test and CEA test.. Biopsies entail taking a sample of a suspected tumor so it can be examined under the microscope. Biopsies for pancreatic cancer are performed as a last resort and entail surgically removing a pancreatic tissue sample and ...
Pancreas Cancer Treatment of Alternative Pancreas Cancer Alternative Neuro Acupuncture Treatment and Pancreas Cancer Herbal Herbs Alternative Medicine Treatment on Pancreas Cancer Treatment Medical Center Pancreas Cancer Remedies
We identified an aberrant accumulation of cholesteryl ester in human pancreatic cancer specimens and cell lines, Li said. Depletion of cholesterol esterification significantly reduced pancreatic tumor growth and metastasis in mice.. Findings show that drugs like avasimibe, previously developed for treatment of atherosclerosis, reduced the accumulation of cholesteryl ester. The disease usually kills within a few months of diagnosis. It is hoped the potential new treatment might extend life of pancreatic cancer patients for a year, Cheng said.. The accumulation of cholesteryl ester is controlled by an enzyme called ACAT-1, and findings correlated a higher expression of the enzyme with a poor survival rate for patients. The researchers analyzed tissue samples from pancreatic cancer patients and then tested the drug treatment in a type of laboratory mice referred to as an orthotopic mouse model, developed at the IU School of Medicine. Specimens of human pancreatic tissues were obtained from the ...
Pancreatic cancer is associated with low responsiveness to conventional chemotherapies and its incidence nearly equals its death rate. This warrants the development of novel mechanism-based approaches for the management of pancreatic cancer. This study was designed to determine the potential of sanguinarine, a plant alkaloid known to possess strong antimicrobial, anti-inflammatory, and antioxidant activities, against human pancreatic carcinoma cells. Employing human pancreatic carcinoma AsPC-1 and BxPC-3 cells, we specifically evaluated the pro-apoptotic and cell cycle deregulatory effects of sanguinarine and evaluated the involvement of Bcl-2 family proteins and p53 as the mechanism of the biological effects of sanguinarine. Our data demonstrated that sanguinarine (at low concentrations of 0.1-10 ?M; for 24 h) treatment to AsPC-1 and BxPC-3 cells resulted in a dose dependent (i) inhibition of viability and growth, (ii) colony formation ability, (iii) induction of apoptosis, and (iv) G0-G1 phase ...
According to the results of a Phase II clinical trial, the addition of the investigational drug EndoTAG™-1 to chemotherapy with Gemzar® (gemcitabine) may improve survival among patients with inoperable pancreatic cancer. These results were presented at the 33rd Congress of the European Society for Medical Oncology (ESMO).. Pancreatic cancer has one of the highest mortality rates of all cancers. It accounts for approximately 2% of all newly diagnosed cancers in the United States each year but 5% of all cancer deaths. Pancreatic cancer is often called a silent killer because its symptoms are usually not recognizable until it has advanced and spread outside the pancreas. As a result the majority of pancreatic cancers are not diagnosed until they have reached advanced stages and are considered incurable.. Chemotherapy is a common treatment for advanced pancreatic cancer. However, due to the poor long-term survival achieved with chemotherapy alone, researchers continue to evaluate novel ways to ...
Natural killer (NK) cells play a key role in non-specific immune response in different cancers, including pancreatic cancer. However the anti-tumor effect of NK cells decreases during pancreatic cancer progression. The regulatory pathways by which NK cells facilitate tumor immune escape are unclear, therefore our purpose was to investigate the roles of the contributory factors. NK cells isolated from fresh healthy peripheral blood were co-cultured with normal human pancreatic ductal cells hTERT-HPNE and human pancreatic cancer cell lines SW1990 and BxPc-3 in vitro. Then NK cell function was determined by Flow cytometric analysis of surface receptors and cytotoxic granules in NK cells, NK cell apoptosis and cytotoxicity, and Enzyme-linked immunosorbent assay of cytokines. Expression level of MMP-9, IDO and COX-2 in hTERT-HPNE and SW1990 cells were detected by quantitative RT-PCR. Statistical differences between data groups were determined by independent t-tests using SPSS 19.0 software. Our results
Tumor microenvironment plays a pivotal role in cancer progression; however, little is known regarding how differences in the microenvironment affect characteristics of cancer cells. Here, we investigated the effects of tumor microenvironment on cancer cells by using mouse tumor models. After 3 cycles of inoculation and extraction of human pancreatic cancer cells, including SUIT-2 and Panc-1 cells, from tumors, distinct cancer cell lines were established; 3P cells from the pancreas obtained using the orthotopic tumor model, and 3sc cells from subcutaneous tissue obtained using the subcutaneous tumor model. On cell re-inoculation of these cells, the 3sc cells and, more prominently, the 3P cells, exhibited higher tumorigenic activity than the parental cells. The 3P cells specifically exhibited low E-cadherin expression and high invasiveness, suggesting that they were endowed with the highest malignant characteristics. RNA-sequence analysis demonstrated that distinct signaling pathways were activated in
TY - JOUR. T1 - Chemosensitization and inhibition of pancreatic cancer stem cell proliferation by overexpression of microRNA-205. AU - Chaudhary, Amit Kumar. AU - Mondal, Goutam. AU - Kumar, Virender. AU - Kattel, Krishna. AU - Mahato, Ram I. PY - 2017/8/28. Y1 - 2017/8/28. N2 - Treatment of pancreatic cancer with gemcitabine (GEM) is limited due to its rapid plasma metabolism and development of chemoresistance. MicroRNA (miRNA) regulates cancer stem cell (CSC) maintenance and induces chemoresistance in cancer cells. In this study, we observed differential downregulation of miR-205 (miR-205-5p) in human pancreatic cancer tissues and cells. Compared to GEM-sensitive MIA PaCa-2 cells, miR-205 was highly downregulated in GEM-resistant MIA PaCa-2R cells. Lentivirus-mediated overexpression of miR-205 inhibits MIA PaCa-2R cell proliferation after GEM-treatment. Further investigation confirmed that miR-205 alone significantly reduces the proliferation of CSCs and tumor growth in mouse models. However, ...
Pancreatic ductal adenocarcinoma has a poor prognosis due to late diagnosis and a lack of effective therapeutic options. Thus, it is important to better understand its molecular mechanisms and to develop more effective treatments for the disease. The ternary complex factor Net, which exerts its strong inhibitory function on transcription of proto-oncogene gene c-fos by forming ternary complexes with a second transcription factor, has been suspected of being involved in pancreatic cancer and other tumors biology. In this study, we found that the majority of pancreatic ductal adenocarcinoma tissues and cell lines had weak or no expression of Net, whereas significantly high level of Net expression occurred in paired adjacent normal tissues we studied. Furthermore, using in vitro and in vivo model systems, we found that overexpression of Net inhibited cell growth and survival and induced cell apoptosis in human pancreatic ductal adenocarcinoma cell PL45; the mechanisms by which Net inhibited the cell cycle
TY - JOUR. T1 - Ex vivo organotypic culture system of precision-cut slices of human pancreatic ductal adenocarcinoma. AU - Misra, Sougat. AU - Moro, Carlos F.. AU - Del Chiaro, Marco. AU - Pouso, Soledad. AU - Sebestyén, A.. AU - Löhr, Matthias. AU - Björnstedt, Mikael. AU - Verbeke, Caroline S.. PY - 2019/12/1. Y1 - 2019/12/1. N2 - Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis, which is mainly due to late diagnosis and profound resistance to treatment. The latter is to a large extent attributed to the tumor stroma that is exceedingly prominent in PDAC and engages in complex interactions with the cancer cells. Hence, relevant preclinical models of PDAC should also include the tumor stroma. We herein describe the establishment and functional validation of an ex vivo organotypic culture of human PDAC that is based on precision-cut tissue slices from surgical specimens and reproducibly recapitulates the complex cellular and acellular composition of PDAC, including its ...
PRIMARY OBJECTIVES:. I. To evaluate progression-free survival (PFS) associated with temozolomide alone or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors.. SECONDARY OBJECTIVES:. I. To evaluate response rates (RR) associated with temozolomide alone or temozolomide and capecitabine treatment in patients with advanced pancreatic neuroendocrine tumors.. II. To evaluate overall survival (OS) associated with temozolomide alone or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors.. III. To evaluate the toxicity associated with temozolomide alone or temozolomide and capecitabine treatment in patients with advanced pancreatic neuroendocrine tumors.. IV. To evaluate the usefulness of methyl guanine methyltransferase (MGMT) status (by immunohistochemistry [IHC] and promoter methylation) for predicting response in pancreatic neuroendocrine tumor patients treated with either temozolomide or temozolomide and capecitabine.. V. To ...
Pancreatic neuroendocrine tumors constitute about 2% of all gastrointestinal neoplasms. Approximately half of the pancreatic neuroendocrine tumors are nonfunctional. Due to lack of specific symptoms, most patients with nonfunctional pancreatic neuroendocrine tumors present with locally advanced or metastatic disease. Second primary malignancies are seen very rarely in these patients. Colon carcinoma ranks third in frequency among primary sites of cancer in both men and women in western countries. Presence of a metachronous colon adenocarcinoma in a patient with nonfunctional pancreatic neuroendocrine tumor has not been reported before. We present a patient who had an asymptomatic mass in the head of the pancreas, detected by ultrasonography in 1996. The patient did not consent to operation. In 2002, after the diagnosis of an unresectable, nonfunctional pancreatic neuroendocrine tumor, interferon alpha-2b and octreotide were started. A year after biological treatment, he refused further ...
2009) Pancreatic cancer stem cells: insights and perspectives. profiling analysis showed that CSLCs (CD44+/CD133+/EpCAM+) exhibit differential expression of more than 1,600 mRNAs, including (2,C4). A large number of studies have shown clear evidence in support of the presence of CSLCs and their clinical implications because the rare subpopulations of CSLCs have been recognized from most tumors, such as prostate, lung, breast, pancreas, brain, gastric, and colorectal tumors. These CSLCs are involved in cell growth, migration/invasion, and apoptosis resistance, attributing to treatment resistance and metastasis, leading to poor clinical end result (2,C4). However, the pathogenesis of CSLCs during tumorigenesis and tumor progression has not been well documented. Although significant improvements have been made in the fight against cancers, pancreatic malignancy (PC) remains one of the most aggressive and lethal malignant diseases in the world, and remains the 4th leading cause of cancer-related ...
In this report, we have identified a subpopulation of highly tumorigenic cancer cells within human pancreatic adenocarcinomas using a xenograft model in which primary human pancreatic adenocarcinoma cells were implanted in immunocompromised mice. These highly tumorigenic cancer cells were identified by expression of the cell surface markers CD44, CD24, and ESA. These cells displayed several features typically seen in stem cells, including the ability to both self-renew and generate differentiated progeny, the ability to differentiate to recapitulate the phenotype of the tumor from which they were derived, and activation of developmental signaling pathways.. We chose to examine expression of the markers CD44, CD24, and ESA based on studies in breast cancer, in which CD44+CD24−/low ESA+ cells were identified as putative cancer stem cells ( 5). We found that cells that expressed CD44, CD24, and ESA represented the most highly tumorigenic population of pancreatic cancer cells, with injection of as ...
TY - JOUR. T1 - Appropriateness of systemic treatments in unresectable metastatic well-differentiated pancreatic neuroendocrine tumors. AU - Strosberg, Jonathan R.. AU - Fisher, George A.. AU - Benson, Al B.. AU - Anthony, Lowell B.. AU - Arslan, Bulent. AU - Gibbs, John F.. AU - Greeno, Edward. AU - Iyer, Renuka V.. AU - Kim, Michelle K.. AU - Maples, William J.. AU - Philip, Philip A.. AU - Wolin, Edward M.. AU - Cherepanov, Dasha. AU - Broder, Michael S.. PY - 2015/2/28. Y1 - 2015/2/28. N2 - AIM: To evaluate systemic treatment choices in unresectable metastatic well-differentiated pancreatic neuroendocrine tumors (PNETs) and provide consensus treatment recommendations. METHODS: Systemic treatment options for pancreatic neuroendocrine tumors have expanded in recent years to include somatostatin analogs, angiogenesis inhibitors, inhibitors of mammalian target of rapamycin and cytotoxic agents. At this time, there is little data to guide treatment selection and sequence. We therefore assembled a ...
PRIMARY OBJECTIVES:. I. To evaluate if the addition of adjuvant everolimus to the R0 or R1 surgical resection of pancreatic neuroendocrine tumor metastases to the liver will result in an improvement in disease free survival.. SECONDARY OBJECTIVES:. I. To evaluate if the addition of adjuvant everolimus to the R0 or R1 surgical resection of pancreatic neuroendocrine tumor metastases to the liver will result in an improvement in overall survival.. II. To evaluate the toxicity associated with adjuvant everolimus following resection in patients with metastatic pancreatic neuroendocrine tumors to the liver.. OUTLINE: Patients are randomized to 1 of 2 treatment arms.. ARM A: Patients receive everolimus orally (PO) once daily (QD) on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.. ARM B: Patients receive placebo PO QD on days on days 1-28. Treatment repeats every 28 days for up to 12 courses in the absence of disease ...
TY - JOUR. T1 - EFFECTS OF HUMAN PANCREATIC TUMOUR GROWTH HORMONE RELEASING FACTOR ON GROWTH HORMONE AND SOMATOMEDIN C LEVELS IN PATIENTS WITH IDIOPATHIC GROWTH HORMONE DEFICIENCY. AU - Borges, João L.C.. AU - Gelato, Marie C.. AU - Rogol, Alan D.. AU - Lee Vance, Mary. AU - Macleod, Robert M.. AU - Lynn Loriaux, D.. AU - Rivier, Jean. AU - Blizzard, Robert M.. AU - Furlanetto, Richard. AU - Evans, William S.. AU - Kaiser, Donald L.. AU - Merriam, George R.. AU - Spiess, Joachim. AU - Vale, Wylie. AU - Thorner, Michael O.. PY - 1983/7/16. Y1 - 1983/7/16. N2 - Human pancreatic tumour growth hormone releasing factor (hpGRF-40) 10 μg/kg was administered intravenously to 6 normal young men and 12 adult patients who had presented in childhood with growth hormone (GH) deficiency (7 patients had isolated GH deficiency, 4 had multiple anterior pituitary hormone deficiencies, and 1 had Hand-Schüller-Christian [HSC] disease). hpGRF-40 administration increased serum GH concentrations in all normal ...
TY - JOUR. T1 - Genome-wide genetic and epigenetic analyses of pancreatic acinar cell carcinomas reveal aberrations in genome stability. AU - Jäkel, Cornelia. AU - Bergmann, Frank. AU - Toth, Reka. AU - Assenov, Yassen. AU - Van Der Duin, Daniel. AU - Strobel, Oliver. AU - Hank, Thomas. AU - Klöppel, Günter. AU - Dorrell, Craig. AU - Grompe, Markus. AU - Moss, Joshua. AU - Dor, Yuval. AU - Schirmacher, Peter. AU - Plass, Christoph. AU - Popanda, Odilia. AU - Schmezer, Peter. PY - 2017/12/1. Y1 - 2017/12/1. N2 - Pancreatic acinar cell carcinoma (ACC) is an aggressive exocrine tumor with largely unknown biology. Here, to identify potential targets for personalized treatment, we perform integrative genome-wide and epigenome-wide analyses. The results show frequently aberrant DNA methylation, abundant chromosomal amplifications and deletions, and mutational signatures suggesting defective DNA repair. In contrast to pancreatic ductal adenocarcinoma, no recurrent point mutations are detected. The ...
Telomerase activity was measured in surgically resected tissues of 20 human pancreatic ductal carcinomas, 12 adenomas, 5 pancreatitis tissues, 14 normal pancreatic ducts, and 13 normal pancreatic tissues (primarily made up of acinar cells) using a PCR-based telomerase assay. Relative telomerase activity was expressed as the equivalent telomerase intensity of the number of cells of a human pancreatic cancer cell line, MIA PaCa-2, per microgram of protein in the tissue samples. The median value (25th percentile, 75th percentile) of relative telomerase activity in pancreatic carcinomas was 13.2 (3.58, 244), which was significantly higher relative to normal tissues, normal ducts, pancreatitis tissues, and adenomas (P , 0.0001). When the cutoff value of relative telomerase activity was set at 1.00 and 3.00, the positivity rates of telomerase activity in pancreatic ductal carcinomas were 100 and 80%, respectively. Some of the adenoma samples displayed a weak telomerase ladder. However, when ...
Trichostatin A (TSA) possess histone deacetylase (HDAC) inhibitory potential, can reverse the deactivation of tumor suppressor genes and inhibit tumor cell proliferation. We evaluated the effect of TSA on HDAC expression, tumor cell proliferation, and cancer stem cells (CSCs) activities in pancreatic ductal adenocarnoma (PDAC) cells. The PDAC cell lines MiaPaCa-2 and PANC-1 were distinctly sensitive to TSA, with enhanced apoptosis, compared to SAHA. TSA or SAHA inhibited vimentin, HDACs 1, 7 and 8, upregulated E-cadherin mRNA and protein levels in the PDAC cells, and time-dependently downregulated Oct-4, Sox-2, and Nanog, as well as inhibited PDAC tumorsphere formation. TSA also induces accumulation of acetylated histones, while increasing histone 3 lysine 4 or 9 dimethylation levels in PDAC cellsand enhancing the epigenetic activity of SAHA. The anti-CSCs effect of TSA was like that obtained by silencing HDAC-1 or 7 using siRNA, and enhances Gemcitabine activity. Our study highlights the ...
Neuroendocrine pancreatic tumours grow slower and metastasise later than ductal and acinar carcinomas. The expression of the p53 tumour suppressor gene in pancreatic neuroendocrine tumour cells is unknown. Pancreatic neuroendocrine cell lines (n = 5) and human tumour tissues (n = 19) were studied for changed p53 coding sequence, transcription, and translation. Proliferative activity of tumour cells was determined analysing Ki-67 expression. No mutation in the p53 nucleotide sequence of neuroendocrine tumour cell was found. However, an overexpression of p53 could be detected in neuroendocrine pancreatic tumour cell lines at a protein level. As no p53 mutations were seen, it is suggested that post-translational events can also lead to an overexpression of p53.. ...
Pancreatic ductal adenocarcinoma (PDAC) shows great cellular heterogeneity, with pronounced epithelial and mesenchymal cancer cell populations. However, the cellular hierarchy underlying PDAC cell diversity is unknown. Here we identify the tetraspanin CD9 as a marker of PDAC tumour-initiating cells. CD9high cells had increased organoid formation capability, and generated tumour grafts in vivo at limiting dilutions. Tumours initiated from CD9high cells recapitulated the cellular heterogeneity of primary PDAC, whereas CD9low cells produced only duct-like epithelial progeny. CD9 knockdown decreased the growth of PDAC organoids, and heterozygous CD9 deletion in Pdx1-Cre; LSL-KRasG12D; p53F/F mice prolonged overall survival. Mechanistically, CD9 promoted the plasma membrane localization of the glutamine transporter ASCT2, enhancing glutamine uptake in PDAC cells. Thus, our study identifies a PDAC subpopulation capable of initiating PDAC and giving rise to PDAC heterogeneity, suggesting that the ...
Glycolytic cancer cells produce large quantities of lactate that must be removed to sustain metabolism in the absence of oxidative phosphorylation. The only venting mechanism described to do this at an adequate rate is H+-coupled lactate efflux on monocarboxylate transporters (MCTs). Outward MCT activity is, however, thermodynamically inhibited by extracellular acidity, a hallmark of solid tumours. This inhibition would feedback unfavourably on metabolism and growth, raising the possibility that other venting mechanisms become important in under-perfused tumours. We investigated connexin-assembled gap junctions as an alternative route for discharging lactate from pancreatic ductal adenocarcinoma (PDAC) cells. Diffusive coupling (calcein transmission) in vitro was strong between Colo357 cells, weaker yet hypoxia-inducible between BxPC3 cells, and very low between MiaPaCa2 cells. Coupling correlated with levels of connexin-43 (Cx43), a protein previously linked to late-stage disease. Evoked lactate
Avarol is a sesquiterpenoid hydroquinone with potent cytotoxicity. Although resolving endoplasmic reticulum (ER) stress is essential for intracellular homeostasis, erratic or excessive ER stress can lead to apoptosis. Here, we reported that avarol selectively induces cell death in pancreatic ductal adenocarcinomas (PDAC), which are difficult to treat owing to the availability of few chemotherapeutic agents. Analyses of the molecular mechanisms of avarol-induced apoptosis indicated upregulation of ER stress marker BiP and ER stress-dependent apoptosis inducer CHOP in PDAC cells but not in normal cells, suggesting that avarol selectively induces ER stress responses. We also showed that avarol activated the PERK-eIF2α pathway but did not affect the IRE1 and ATF6 pathways. Moreover, CHOP downregulation was significantly suppressed by avarol-induced apoptosis. Thus, the PERK-eIF2α-CHOP signaling pathway may be a novel molecular mechanism of avarol-induced apoptosis. The present data indicate that avarol
TY - JOUR. T1 - Colon and pancreas tumors enhance coagulation. T2 - Role of hemeoxygenase-1. AU - Nielsen, Vance G.. AU - Nfonsam, Valentine N.. AU - Matika, Ryan W.. AU - Ong, Evan S.. AU - Jie, Tun. AU - Warneke, James A.. AU - Steinbrenner, Evangelina B.. PY - 2014/7. Y1 - 2014/7. N2 - Colon and pancreatic cancer are associated with significant thrombophilia. Colon and pancreas tumor cells have an increase in hemeoxygenase-1 (HO-1) activity, the endogenous enzyme responsible for carbon monoxide production. Given that carbon monoxide enhances plasmatic coagulation, we determined if patients undergoing resection of colon and pancreatic tumors had an increase in endogenous carbon monoxide and plasmatic hypercoagulability. Patients with colon (n = 17) and pancreatic (n = 10) tumors were studied. Carbon monoxide was determined by the measurement of carboxyhemoglobin (COHb). A thrombelastographic method to assess plasma coagulation kinetics and formation of carboxyhemefibrinogen (COHF) was ...
Development of systems that reconstitute hallmark features of human pancreatic intraepithelial neoplasia (PanINs), the precursor to pancreatic ductal adenocarcinoma, could generate new strategies for early diagnosis and intervention. However, human cell-based PanIN models with defined mutations are unavailable. Here, we report that genetic modification of primary human pancreatic cells leads to development of lesions resembling native human PanINs. Primary human pancreas duct cells harbouring oncogenic KRAS and induced mutations in CDKN2A, SMAD4 and TP53 expand in vitro as epithelial spheres. After pancreatic transplantation, mutant clones form lesions histologically similar to native PanINs, including prominent stromal responses. Gene expression profiling reveals molecular similarities of mutant clones with native PanINs, and identifies potential PanIN biomarker candidates including Neuromedin U, a circulating peptide hormone. Prospective reconstitution of human PanIN development from primary cells
In February of this year the U.S. National Cancer Institute published an important overview of the state of the science and medicine of pancreatic cancer. We will comment on aspects of it from time to time in the future, but as it so comprehensive and precise, in a departure from our usual practice, we will show a copy it here (sans bibliography and figures) in our pancreatic cancer blog. The term Pancreatic Ductal Carcinoma is accurate and abbreviated PDAC in the original paper; here in the interests of a potential lay reader we will add in parentheses the term: pancreatic cancer.. Scientific Framework for Pancreatic Ductal Carcinoma Executive Summary Significant scientific progress has been made in the last decade in understanding the biology and natural history of pancreatic ductal adenocarcinoma (PDAC, pancreatic cancer); major clinical advances, however, have not occurred. Although PDAC (pancreatic cancer) shares some of the characteristics of other solid malignancies, such as mutations ...
TY - JOUR. T1 - CPI-613 rewires lipid metabolism to enhance pancreatic cancer apoptosis via the AMPK-ACC signaling. AU - Gao, Lixia. AU - Xu, Zhigang. AU - Huang, Zheng. AU - Tang, Yan. AU - Yang, Donglin. AU - Huang, Jiuhong. AU - He, Leilei. AU - Liu, Manran. AU - Chen, Zhongzhu. AU - Teng, Yong. N1 - Publisher Copyright: © 2020 The Author(s).. PY - 2020/4/28. Y1 - 2020/4/28. N2 - Background: Pancreatic cancer remains one of the most rapidly progressive and deadly malignancies worldwide. Current treatment regimens only result in small improvements in overall survival for patients with this cancer type. CPI-613 (Devimistat), a novel lipoate analog inhibiting mitochondrial metabolism, shows the new hope for pancreatic cancer treatment as an efficient and well-tolerated therapeutic option treated alone or in combination with chemotherapy. Methods: Pancreatic cancer cells growing in planar 2D cultures and 3D scaffold were used as research platforms. Cell viability was measured by MTT and ...
TY - JOUR. T1 - Co-expression of mesothelin and CA125 correlates with unfavorable patient outcome in pancreatic ductal adenocarcinoma. AU - Einama, Takahiro. AU - Kamachi, Hirofumi. AU - Nishihara, Hiroshi. AU - Homma, Shigenori. AU - Kanno, Hiromi. AU - Takahashi, Kenta. AU - Sasaki, Ayami. AU - Tahara, Munenori. AU - Okada, Kuniaki. AU - Muraoka, Shunji. AU - Kamiyama, Toshiya. AU - Matsuno, Yoshihiro. AU - Ozaki, Michitaka. AU - Todo, Satoru. PY - 2011/11. Y1 - 2011/11. N2 - Objectives: Recent studies have shown that the high affinity of mesothelin-CA125 interaction might cause intracavitary tumor metastasis. We examined the clinicopathologic significance and prognostic implication of mesothelin and CA125 expression in pancreatic ductal adenocarcinoma. Methods: Tissue samples from 66 pancreatic ductal adenocarcinomas were immunohistochemically examined. Proportion and intensity of constituent tumor cells with mesothelin and CA125 expression were analyzed and classified as high-level ...
Pancreatic cancer is lethal, as it is often detected late. Thus, novel biomarkers of precursor lesions are needed to devise timely therapies. Pancreatic intraepithelial neoplasia (PanIN) and intraductal papillary mucinous neoplasm (IPMN) are major precursors of pancreatic cancer. In normal gastric mucosa, gastric gland mucin-specific O-glycans are unique in having α1,4-linked N-acetylglucosamine (αGlcNAc) residues attached to MUC6. Recently we reported that αGlcNAc functions as a tumor suppressor for differentiated-type gastric adenocarcinoma (Karasawa et al., J Clin Invest 122, 923, 2012). MUC6 is also expressed in pancreatic neoplasms, including PanIN and IPMN, but the role of αGlcNAc expression in pancreatic neoplasms remains unknown. Here, we analyze expression patterns of αGlcNAc, MUC6 and MUC5AC in pancreatic neoplasms and compare them with progression from PanIN to invasive ductal adenocarcinoma (IDAC) (the PanIN-IDAC sequence; 20 cases) and from IPMN to IPMN with associated invasive
TY - JOUR. T1 - Grading of well-differentiated pancreatic Neuroendocrine tumors is improved by the inclusion of both ki67 Proliferative index and mitotic rate. AU - McCall, Chad M.. AU - Shi, Chanjuan. AU - Cornish, Toby C.. AU - Klimstra, David S.. AU - Tang, Laura H.. AU - Basturk, Olca. AU - Mun, Liew Jun. AU - Ellison, Trevor A.. AU - Wolfgang, Christopher L.. AU - Choti, Michael A.. AU - Schulick, Richard D.. AU - Edil, Barish H.. AU - Hruban, Ralph H.. PY - 2013/11. Y1 - 2013/11. N2 - The grading system for pancreatic neuroendocrine tumors (PanNETs) adopted in 2010 by the World Health Organization (WHO) mandates the use of both mitotic rate and Ki67/MIB-1 index in defining the proliferative rate and assigning the grade. In cases when these measures are not concordant for grade, it is recommended to assign the higher grade, but specific data justifying this approach do not exist. Thus, we counted mitotic figures and immunolabeled, using the Ki67 antibody, 297 WHO mitotic grade 1 and 2 ...
BACKGROUND: Histologic characteristics have proven to be very useful for classifying different types of tumors of the pancreas. As a result, the major tumor types in the pancreas have long been classified based on their microscopic appearance. MAIN BODY: Recent advances in whole exome sequencing, gene expression profiling, and knowledge ... read more of tumorigenic pathways have deepened our understanding of the underlying biology of pancreatic neoplasia. These advances have not only confirmed the traditional histologic classification system, but also opened new doors to early diagnosis and targeted treatment. CONCLUSION: This review discusses the histopathology, genetic and epigenetic alterations and potential treatment targets of the five major malignant pancreatic tumors - pancreatic ductal adenocarcinoma, pancreatic neuroendocrine tumor, solid-pseudopapillary neoplasm, acinar cell carcinoma and pancreatoblastoma. show less ...
Image via Wikipedia A new drug combination tested in mice may target the cells responsible for driving some pancreatic tumors. The combination of gemcitabi
View details of top pancreatic neuroendocrine tumor hospitals in Navi Mumbai. Get guidance from medical experts to select best pancreatic neuroendocrine tumor hospital in Navi Mumbai
The combination of Afinitor® (everolimus) and Temodar® (temozolomide) appears to be active against advanced pancreatic neuroendocrine tumors. The details of this Phase I/II study were presented at the 2010 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium.[1]. Neuroendocrine tumors form from cells that release hormones in response to a signal from the nervous system. These tumors include carcinoid tumors, islet cell tumors, medullary thyroid carcinomas, pheochromocytomas, and Merkel cell carcinomas. Although they can occur in many different parts of the body, neuroendocrine tumors often develop in the digestive system.. Afinitor is an oral targeted therapy that works by inhibiting a protein known as the mammalian target of rapamycin (mTOR). The mTOR protein plays an important role in regulating cancer cell division and blood vessel growth. It was approved in 2009 for the treatment of selected patients with advanced renal cell (kidney) cancer.. The combination of ...
The tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) is a specific and potent inducer of apoptosis in cancer cells, but the resistance of many tumour cells to TRAIL still represents a major hurdle for the clinical treatment of tumours with TRAIL. As apoptosis is regulated by the balance of activities of several anti-apoptotic factors and pro-apoptotic factors, we analysed the relative contribution of the two sides and found that down-regulation of Bcl-x L and in particular XIAP, but not c-Flip, sensitised the TRAIL resistant pancreatic cancer cell line Panc-1. A combination of both XIAP and Bcl-x L knock-downs showed no substantial added benefit indicating that both act in the same pathway. Notably, the degree of sensitisation by silencing of anti-apoptotic genes was further elevated by concomitantly increasing the pro-apoptotic potential in Panc-1 cells through over-expression of TRAIL-R1 or IFN-γ-mediated increases in caspase-8 levels. Similar sensitisation effects were ...
BONITA, CA--(Marketwired - October 09, 2015) - The combination of PharmaCyte Biotechs (OTCQB: PMCB) signature live-cell encapsulation technology, Cell-in-a-Box® with low doses of ifosfamide has already won the FDAs Orphan Drug status here in the U.S
TY - JOUR. T1 - SIRT1-Activating compounds (STAC) negatively regulate pancreatic cancer cell growth and viability through a SIRT1 lysosomal-dependent pathway. AU - Chini, Claudia C.S.. AU - Espindola-Netto, Jair M.. AU - Mondal, Gourish. AU - Guerrico, Anatilde M.Gonzalez. AU - Nin, Veronica. AU - Escande, Carlos. AU - Sola-Penna, Mauro. AU - Zhang, Jin San. AU - Billadeau, Daniel D.. AU - Chini, Eduardo N.. N1 - Funding Information: Grant Support This work was supported by the Pancreatic Cancer SPORE project from NIH/ NCIto E.N. Chini (grant: CA102701-08) and the Mayo Clinic Center for Cell Signaling in Gastroenterology (NIDDK P30DK084567). J.M. Espindola-Netto is a recipient of a grant from Coordenac?o de Aperfeicoamento de Pessoal de N?vel Superior (CAPES) and Conselho Nacional de Desenvolvimento Cient?fico e Tecnologico (CNPq). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in ...
BAG3 Directly Stabilizes Hexokinase 2 mRNA and Promotes Aerobic Glycolysis in Pancreatic Cancer Cells Scientists showed that aberrant expression of BAG3 significantly contributes to the reprogramming of glucose metabolism in pancreatic ductal adenocarcinoma cells. [J Cell Biol] Abstract Long Noncoding RNA NORAD, a Novel Competing Endogenous RNA, Enhances the Hypoxia-Induced Epithelial-Mesenchymal Transition to Promote Metastasis in Pancreatic Cancer NORAD expression was measured in 33 paired cancerous and noncancerous tissue samples by real-time PCR. The effects of NORAD on pancreatic cancer cells were studied by overexpression and knockdown in vitro. [Mol Cancer] Full Article A New Panel of Pancreatic Cancer Biomarkers Discovered Using a Mass Spectrometry-Based Pipeline Scientists developed a coherent, high-throughput and non-discriminatory pipeline for the novel clinical biomarker discovery of pancreatic carcinoma. [Br J Cancer] Abstract Alternative Polyadenylation of ZEB1 Promotes Its ...
Despite advances in surgery, radiotherapy, and chemotherapy, pancreatic adenocarcinoma often progresses rapidly and causes death. The physical decline of these patients is expected to impact their quality of life (QoL). Therefore, in addition to objective measures of effectiveness, the evaluation of health-related QoL should be considered a matter of major concern when assessing therapy outcomes. Observational, prospective, multicenter study including patients with metastatic pancreatic adenocarcinoma who started first-line chemotherapy in 12 Spanish centers. Treatment and clinical characteristics were recorded at baseline. Patients health-related quality of life, ECOG, and Karnofsky index were measured at baseline, at Days 15 and 30, and every four weeks up to 6 months of chemotherapy. Health-related quality of life was measured using the EORTC-QLQ-C30 and EQ-5D questionnaires. Other endpoints included overall survival and progression-free survival. The study sample included 116 patients (median age
Growing tumors are hypoxic and respond to microenvironmental stress through increased expression of the hypoxia inducible factor-1α (HIF-1α) transcription factor, resulting in an adaptive switch to glycolytic metabolism, angiogenic signaling, survival, and metastasis. HIF-1α expression is associated with tumor resistance to cytotoxic therapy and inferior patient outcomes. Pancreatic cancer is the most hypoxic of all solid tumors and remains refractory to current chemoradiotherapy. We have seen nuclear HIF-1α in 88% of human pancreatic ductal carcinoma but in only 16% of normal pancreas. Stroma adjacent to the pancreatic ductal carcinoma also showed HIF-1α in 43% of cases. We investigated the novel selective HIF-1α inhibitor PX-478 on in vitro and in vivo radiation response of human pancreatic cancer models. Inhibition of HIF-1α by PX-478 increased cell killing by radiation. In mice with Panc-1, CF-PAC-1, or SU.86.86 pancreatic xenografts, concurrent administration of PX-478 potentiated ...
Cancer stem cells (CSCs) have been studied for their self-renewal capacity and pluripotency, as well as their resistance to anticancer therapy and their ability to metastasize to distant organs. CSCs are difficult to study because their population is quite low in tumor specimens. To overcome this problem, we established a culture method to induce a pancreatic cancer stem-like cell (P-CSLC)-enriched population from human pancreatic cancer cell lines. Human pancreatic cancer cell lines established at our department were cultured in CSC-inducing media containing epidermal growth factor (EGF), basic fibroblast growth factor (bFGF), leukemia inhibitory factor (LIF), neural cell survivor factor-1 (NSF-1), and N-acetylcysteine. Sphere cells were obtained and then transferred to a laminin-coated dish and cultured for approximately two months. The surface markers, gene expression, aldehyde dehydrogenase (ALDH) activity, cell cycle, and tumorigenicity of these induced cells were examined for their stem ...
TY - JOUR. T1 - Palliative care in advanced pancreatic cancer. AU - Muircroft, Wendy. AU - Currow, David. PY - 2016/3. Y1 - 2016/3. N2 - The management of patients with advanced pancreatic cancer often requires a multi-disciplinary approach with individualised therapy. Addressing the underlying causes of several of the troublesome symptoms that are relatively unique to the pathophysiology of pancreatic cancer is crucial in order to optimise the function and comfort of people diagnosed with this poor prognosis cancer. Early recognition and response is likely to improve outcomes later in the course of the disease, but more work needs to be done to compare expectant and reactive approaches to the most troublesome symptoms in advanced pancreatic cancer. Given such a poor outlook, referral to a palliative care service that has an active, team-based approach that includes dietetics, gastroenterology, interventional pain expertise and liaison psychiatry is likely to deliver the best possible outcomes. ...
Cystic pancreatic tumors are detected with increasing frequency and remain a clinical problem. Since they have different potential of malignancy the management and decision making process is a hard task. Guidelines, concerning pancreatic cystic tumors indicate the management with mucinous, serous cystic pancreatic neoplasms and solid pseudopappilary tumor, while the management with pancreatic cystic neuroendocrine tumors is not included into these standards. This review tries to answer the question are the cystic pancreatic neuroendocrine tumors different entity from solid tumors of neuroendocrine origin.The management and differential diagnosis of these neoplasms with special focus on features on imaging studies allowing preoperative diagnosis are discussed ...
Less than 5% of pancreatic tumors are Pancreatic Neuroendocrine Tumors (also called PNETs or islet cell tumors). Learn about PNETs and our patient services.
A carbohydrate, mannose-binding lectin or MBL, carried on the surface of a species of acne-causing fungi, Malassezia, has been shown to cause carcinogenesis and an increase in Pancreatic Ductal Adenocarcinoma (PDA); the fungus levels increase significantly in the pancreas prior to the disease.. Furthermore, when researchers(1) ablated the mycobiome (the fungal or yeast microbiome) of the pancreas, slow to moderate cancers stopped progressing. But when they introduced Malassezia strains - but not Candida Saccharomyces or Aspergillus strains - the cancer accelerated. Malassezia is a species of fungi (funghi) or yeast naturally found on the skin of most animals and humans. It is thought to lie behind fungal acne.. At CANCERactive, we have covered several studies showing that bacteria from the mouth associated with gum disease were linked to Pancreatic Cancer, and that a sudden rush of bacteria from the gut to the pancreas caused a 1000-fold increase in bacteria in the pancreatic microbiome and ...
"Expertscape: Pancreatic Neoplasms, November 2018". expertscape.com. November 2018. Retrieved 2018-11-26.. ... In November 2018 Expertscape recognized TUM as #10 in the world for expertise in Pancreatic Cancer.[17] ...
"Expertscape: Pancreatic Neoplasms, November 2018". expertscape.com. November 2018. Retrieved 2018-11-26. "Video: Interview with ... His surgical focus is on hepatobiliary, colorectal, and pancreatic surgery and transplant surgery. As a surgeon, he has ... Büchler as #3 in the world for expertise in Pancreatic Cancer. Diseases of the Pancreas: Acute Pancreatitis, Chronic ... He is co-author of more than 2,500 scientific publications focused on gastrointestinal cancers, pancreatic diseases and ...
"Expertscape: Pancreatic Neoplasms, November 2018". expertscape.com. November 2018. Retrieved 2018-11-26. "Best Universities In ... In November 2018 Expertscape recognized it as #9 in the world for expertise in Pancreatic Cancer. University of Tokyo was ...
"Expertscape: Pancreatic Neoplasms, November 2018". expertscape.com. November 2018. Retrieved 26 November 2018. Michael Proft. ( ... the world as of 2020 In November 2018 Expertscape recognized it as one of the top ten institutions in the world in pancreatic ...
Ellis, C. T.; Barbour, J. R.; Shary, T. M.; Adams, D. B. (2010). "Pancreatic cyst: Pseudocyst or neoplasm? Pitfalls in ... Morgan, K. A.; Fontenot, B. B.; Harvey, N. R.; Adams, D. B. (2010). "Revision of anastomotic stenosis after pancreatic head ... Theruvath, T. P.; Morgan, K. A.; Adams, D. B. (2010). "Mucinous cystic neoplasms of the pancreas: How much preoperative ... Morgan, K.; Mansker, D.; Adams, D. B. (2010). "Not Just for Trauma Patients: Damage Control Laparotomy in Pancreatic Surgery". ...
"Pancreatic ductal and acinar cell neoplasms in Carney complex: a possible new association". J Clin Endocrinol Metab. 96 (11): ... Epithelioid blue nevus List of cutaneous neoplasms associated with systemic syndromes Carney Syndrome at eMedicine Carney, J.; ...
Additionally, it has been demonstrated as an independent prognostic factor in patients with pancreatic neuroendocrine neoplasms ... "Prognostic relevance of proliferation-related miRNAs in pancreatic neuroendocrine neoplasms". European Journal of Endocrinology ...
最後一種則是主要發生在女性的胰黏液性囊狀腫瘤(英語:pancreatic mucinous cystic neoplasm)(MCNs),它可能維持良性或發展為惡性[61]。如果腫瘤變大、造成異常症狀或有任何可疑的特徵,醫師通常能藉由手術將腫瘤完整切除[ ... 胰黏液性囊性腫瘤(英語:Pancreatic mucinous cystic neoplasm)包含多種胰臟腫瘤,且惡性程度不一。隨著電腦
A rare form of pancreatic neoplasm". Diagnostic Cytopathology. 43: 251-256. doi:10.1002/dc.23195. Vlachostergios, Panagiotis J ... They can arise in several parts of the body, and thus form sub-types of diseases such as stomach cancer and pancreatic cancer. ... Hepatoid tumor or hepatoid [adeno]carcinoma are terms for a number of uncommon or rare neoplasms in humans, named for a visual ... Soofi, Yousef; Kanehira, Kazunori; Abbas, Ali; Aranez, Jose; Bain, Andrew; Ylagan, Lourdes (August 2014). "Pancreatic hepatoid ...
revdel) Pancreatic serous cystadenoma. *(speedy) User:Amaitra1/Serous cystic neoplasms. *(request speedy, got stubify) ...
2006). "Aberrant methylation of the Human Hedgehog interacting protein (HHIP) gene in pancreatic neoplasms". Cancer Biol. Ther ...
Pancreatic Neoplasms, November 2018". expertscape.com. November 2018. Retrieved 2018-11-26. http://halstedthedocumentary.org/. ... He is currently Director of the Sol Goldman Pancreatic Cancer Research Center at Johns Hopkins, Director of the Division of ... He is a world expert on pancreatic cancer. Hruban received his undergraduate degree from the University of Chicago, and his ... In November 2018, Expertscape recognized him as one of the world's foremost experts in pancreatic cancer. He also produced an ...
This type of malignant neoplasm mimics pancreatic development at 7 weeks of gestation and tends to afflict, most commonly, ... About 0.5% to 1% of all primary malignant lung tumors are childhood tumors of the lung, making it a rare form of neoplasm. ... Retinoblastoma is a rare form of eye neoplasm (found in the retina) that is mostly found in children, being the most common ...
... involving the dysfunction of DUSP6/MKP-3 in pancreatic intraepithelial neoplasia and intraductal papillary-mucinous neoplasms ... Xu S, Furukawa T, Kanai N, Sunamura M, Horii A (2005). "Abrogation of DUSP6 by hypermethylation in human pancreatic cancer". ... in pancreatic cancer". Cytogenetics and Cell Genetics. 82 (3-4): 156-9. doi:10.1159/000015091. PMID 9858808. S2CID 46883904. ... "Potential tumor suppressive pathway involving DUSP6/MKP-3 in pancreatic cancer". The American Journal of Pathology. 162 (6): ...
MeSH website, tree at: "Pancreatic Neoplasms [C04.588.322.475]", accessed 16 October 2014 Sotoudehmanesh R, Hedayat A, ... Insulinoma is one of the most common types of tumors arising from the islets of Langerhans cells (pancreatic endocrine tumors ... Sometimes, angiography with percutaneous transhepatic pancreatic vein catheterization to sample the blood for insulin levels is ... Insulinomas are one of the functional pancreatic neuroendocrine tumor (PNET) group ("functional" because it increases ...
Pancreatic cancer Pancreatic mucinous cystic neoplasm Serous cystadenoma of the pancreas Patil TB, Shrikhande SV, Kanhere HA, ... Stömmer P, Kraus J, Stolte M, Giedl J (March 1991). "Solid and cystic pancreatic tumors. Clinical, histochemical, and electron ... A solid pseudopapillary tumour is a low-grade malignant neoplasm of the pancreas of papillary architecture that typically ... they are negative for chromogranin and pancreatic enzymes. The diagnosis of solid pseudopapillary tumour of the pancreas is ...
Case report: ectopic pancreatic rest in the proximal stomach mimicking gastric neoplasms. Clin Radiol. 2007 Jun;62(6):600-2. ... When seen on upper gastrointestinal series, a pancreatic rest may appear to be a submucosal mass or gastric neoplasm. Most are ... A myoepithelial hamartoma, also known as a pancreatic rest, is ectopic pancreatic tissue found in the stomach, duodenum, or ... A hamartoma is a mostly benign, local malformation of cells that resembles a neoplasm of local tissue but is usually due to an ...
Possible causes include:[citation needed] Neoplasm Carbohydrate malabsorption Pancreatic cancer Polycystic ovary syndrome (PCOS ... Type 1 diabetes only occurs when pancreatic beta-cell function is impaired. Hyperinsulinemia can be seen in a variety of ... Adipocytes will generate triglycerides in the presence of insulin but refers to a liver condition rather than a pancreatic one ... To compensate for the increased blood glucose levels, fetal pancreatic beta cells can undergo hyperplasia. The rapid division ...
Pancreatic mucinous cystic neoplasms are a broad group of pancreas tumors that have varying malignant potential. They are being ... List of people diagnosed with pancreatic cancer. References[edit]. *^ a b c d e f g "Pancreatic Cancer Treatment (PDQ®) Patient ... Micrographs of normal pancreas, pancreatic intraepithelial neoplasia (precursors to pancreatic carcinoma) and pancreatic ... "Pancreatic Cancer - Cancer Stat Facts". SEER. Retrieved 4 April 2019.. *^ a b "Pancreatic Cancer Treatment (PDQ®) Health ...
... pancreatic neoplasm and/or pancreatic trauma. Pancreatic pseudocysts are sometimes called false cysts because they do not have ... Pancreatic pseudocysts account for approximately 75% of all pancreatic masses. Signs and symptoms of pancreatic pseudocyst ... A pancreatic pseudocyst is a circumscribed collection of fluid rich in pancreatic enzymes, blood, and necrotic tissue, ... Diagnosis of Pancreatic pseudocyst can be based on cyst fluid analysis: Carcinoembryonic antigen (CEA) and CA-125 (low in ...
The pancreatic tumors (or pancreatic neoplasms) are tumors arising in the pancreas. There are several types, which can be ... either benign or malignant (pancreatic cancer). Robbins and Cotran Pathologic Basis of Disease (9 ed.). Elsevier. 2015. pp. 883 ...
The most common malignancy that can present as a pancreatic cyst is a mucinous cystic neoplasm. Cysts from 1-5 mm on CT or ... A pancreatic cyst is a fluid filled sac within the pancreas. Causes range from benign to malignant. Pancreatic cysts can occur ... Main branch intraductal papillary mucinous neoplasms (IPMNs) are associated with dilatation of the main pancreatic duct, while ... MRCP can help distinguish the position of the cysts relative to the pancreatic duct, and direct appropriate treatment and ...
... such as the intraductal papillary mucinous neoplasm and the mucinous cystic neoplasm), serous cystic neoplasms are almost ... "Pathology of Neoplasms of the Pancreas". Johns Hopkins University. Retrieved 25 April 2010. "Pancreatic Surgery". Johns Hopkins ... Ovarian serous cystadenoma Pancreatic mucinous cystadenoma Solid pseudopapillary neoplasm Jais, B; Rebours, V; Malleo, G; ... mixed serous-endocrine neoplasm, and VHL-associated serous cystic neoplasm. This latter classification scheme is useful because ...
... "pancreatic endocrine tumors" are neuroendocrine neoplasms that arise from cells of the endocrine (hormonal) and nervous system ... are different from the mutated genes previously found in pancreatic adenocarcinoma. one in six well-differentiated pancreatic ... Pancreatic neuroendocrine tumor staging (AJCC) Stage T1 Stage T2 Stage T3 Stage T4 Involvement of nearby lymph nodes - Stage N1 ... Pancreatic neuroendocrine tumors may arise in the context of multiple endocrine neoplasia type 1, Von Hippel-Lindau disease, ...
... pancreatic cancer). Serous cystadenoma of the pancreas Solid pseudopapillary neoplasm Zollinger-Ellison syndrome is a ... Other pancreatic diseases include Diabetes mellitus, Exocrine pancreatic insufficiency, Cystic fibrosis, Pseudocysts, Cysts, ... A pancreatic pseudocyst is a circumscribed collection of fluid rich in amylase and other pancreatic enzymes, blood and necrotic ... Exocrine pancreatic insufficiency (EPI) is the inability to properly digest food due to a lack of digestive enzymes made by the ...
... benign and metastatic neoplasms (such as breast cancer, pancreatic cancer, and oral cancer), infectious conditions (such as HIV ... In a 2011 review article that examined pancreatic cancer biomarkers, Hamade and Shimosegawa concluded that clinical application ... Hamada S, Shimosegawa T (2011). "Biomarkers of pancreatic cancer". Pancreatology. 11 Suppl 2 (2): 14-9. doi:10.1159/000323479. ... March 2010). "Salivary transcriptomic biomarkers for detection of resectable pancreatic cancer". Gastroenterology. 138 (3): 949 ...
... (MCN) is a type of cystic lesion that occurs in the pancreas. Amongst individuals ... Intraductal papillary mucinous neoplasm Pancreatic serous cystadenoma Elta, GH; Enestvedt, BK; Sauer, BG; Lennon, AM (April ... "Pancreatic mucinous cystic neoplasm defined by ovarian stroma: demographics, clinical features, and prevalence of cancer". ... The diagnosis of pancreatic MCN is typically achieved with imaging. If the results of imaging (CT/MRI) are unclear, then ...
Pancreatic serous cystadenoma Solid pseudopapillary neoplasm "Intraductal Papillary Mucinous Neoplasms of the Pancreas". Johns ... Intraductal papillary mucinous neoplasm (IPMN) is a type of tumor that can occur within the cells of the pancreatic duct. IPMN ... Although intraductal papillary mucinous neoplasms are benign tumors, they can progress to pancreatic cancer. As such IPMN is ... "Pancreatic Surgery". Johns Hopkins University. Retrieved 7 September 2009. "Laproscopic Pancreatic Surgery". Johns Hopkins ...
... "pancreatic endocrine tumors"[3][4] are neuroendocrine neoplasms that arise from cells of the endocrine (hormonal) and nervous ... Pancreatic neuroendocrine tumors (PanNETs, PETs, or PNETs), often referred to as "islet cell tumors",[1][2] or " ... a b Everolimus Approved for Pancreatic Neuroendocrine Tumors. The ASCO Post. May 15, 2011, Volume 2, Issue 8 "Archived copy". ... Oberg, K (2010). "Pancreatic endocrine tumors". Seminars in Oncology. 37 (6): 594-618. doi:10.1053/j.seminoncol.2010.10.014. ...
... pancreatic adenocarcinoma, cervical carcinoma, gastric carcinoma, squamous-cell carcinoma of the oral cavity and oropharynx, ... hCG was discovered to be expressed in certain kinds of malignant neoplasms, including breast cancer, adenocarcinoma of the ... "Beta human chorionic gonadotropin concentrations in serum of patients with pancreatic adenocarcinoma". Gut. 42: 88-91. doi: ...
... aka Hurthle-Cell Neoplasms).[15] Tumors expressing the PAX8/PPARy are usually present in at a young age, small in size, present ... pancreatic islet cells and lymphoid cells.[8] PAX8 and other transcription factors play a role in binding to DNA and regulating ...
Salivary gland neoplasm. *Sarcoma. *Skin cancer. *Small intestine cancer. *Small-cell carcinoma ...
Farrell JJ, Fernández-del Castillo C (juni 2013). "Pancreatic cystic neoplasms: management and unanswered questions". ... "Pancreatic cancer research". Cancer Research UK. Hentet 17. juli 2014.. *^ "Australian Pancreatic Genome Initiative". Garvan ... Pancreatic Neuroendocrine Tumors *^ Tejani MA, Saif MW (2014). "Pancreatic neuroendocrine tumors: Does chemotherapy work?". JOP ... Pancreatic, neuroendocrine GI, and adrenal cancers. Cancer Management: A Multidisciplinary Approach 13th edition 2010. ISBN 978 ...
Pancreatic ductal carcinoma. *cystic neoplasms: Serous microcystic adenoma. *Intraductal papillary mucinous neoplasm ...
腦垂腺(英语:Pituitary neoplasm). *垂體腺瘤(英语:Pituitary adenoma):泌乳素瘤(英语:Prolactinoma) ... 胰腺神經內分泌腫瘤(英语:Pancreatic neuroendocrine tumor)(PanNETs) ... 腫瘤:內分泌腺腫瘤(英语:Endocrine gland neoplasm)(C73-
In 2016, the WHO revised their classification of myeloproliferative neoplasms to define Prefibrotic primary myelofibrosis as a ... "Hepatobiliary & Pancreatic Diseases International : HBPD INT. 9 (6): 651-3. PMID 21134837.. ... These mutations are not specific to myelofibrosis, and are linked to other myeloproliferative neoplasms, specifically ... Barosi, Giovanni (2011). "Conventional and Investigational Therapy for Primary Myelofibrosis". Myeloproliferative Neoplasms. pp ...
This is particularly true of complex cancer resections such as pancreaticoduodenectomy (Whipple procedure) for pancreatic ... While many general surgeons are actively involved in treating patients with malignant neoplasms, the designation of "surgical ...
... see malignant neoplasms). Thus, CpG island hyper/hypo-methylation in the promoters of DNA repair genes are likely central to ... "Exploration of global gene expression patterns in pancreatic adenocarcinoma using cDNA microarrays". Am. J. Pathol. 162 (4): ...
King JC, Ng TT, White SC, Cortina G, Reber HA, Hines OJ (October 2009). "Pancreatic serous cystadenocarcinoma: a case report ... Cystadenocarcinoma is a malignant form of a cystadenoma and is a malignant neoplasm derived from glandular epithelium, in which ...
8560-8580) Complex epithelial neoplasms. Carcinoma In situ[edit]. The term carcinoma in situ (or CIS) is a term for cells that ... Pancreas: Pancreatic carcinoma is almost always of the adenocarcinoma type and is highly lethal. ... and imaging studies in a logical fashion to obtain information about the size of the neoplasm and the extent of its invasion ... or other notable characteristics consistent with a more highly differentiated neoplasm. ...
Craniopharyngioma is a neoplasm which can arise from the epithelium within the cleft. ...
They form a subset of neoplasms. A neoplasm or tumor is a group of cells that have undergone unregulated growth and will often ... "Screening for Pancreatic Cancer". U.S. Preventive Services Task Force. 2004. Archived from the original on 21 November 2010.. ... Routine screening is not recommended for bladder cancer,[136] testicular cancer,[137] ovarian cancer,[138] pancreatic cancer,[ ... pancreatic cancer, prostate cancer, skin cancer, and thyroid cancer as well as other cancer types.[145] ...
Pancreatic ductal carcinoma. *cystic neoplasms: Serous microcystic adenoma. *Intraductal papillary mucinous neoplasm ...
Hoption Cann SA, Gunn HD, van Netten JP, van Netten C. (2004) "Spontaneous regression of pancreatic cancer" Case Reports and ... Coley, William (1949). Neoplasms of Bone. New York: Medical Book Department of Harper & Brothers. pp. 565-570.. ...
As most early-stage cancers are asymptomatic, neoplasm of the gallbladder is found in late stages and has a poor prognosis. ... In testing for gallbladder disease, specifically, liver panel tests and pancreatic enzymes such as lipase will be within normal ... Gallbladder cancer (Malignant neoplasm of the gallbladder) is rare, and most of the time is adenocarcinoma. ... If gallstones are blocking other biliary tract areas causing pancreatic gallstones or choledocholithiasis, elevated liver panel ...
Pancreatic ductal carcinoma. *cystic neoplasms: Serous microcystic adenoma. *Intraductal papillary mucinous neoplasm ...
Ellison TA, Edil BH (2012). "The current management of pancreatic neuroendocrine tumors". Adv Surg (46): 283-296. PMID 22873046 ... Glandular and epithelial neoplasms (ICD-O 8010-8589). Epithelium. Papilloma/carcinoma. (8010-8139). *Small cell carcinoma ... Increased levels of somatostatin inhibit pancreatic hormones and gastrointestinal hormones. Thus somatostatinomas are ...
Cancers, most particularly pancreatic, but not cancers of the lip, oral cavity, and pharynx[10] ... Myeloproliferative neoplasms including essential thrombocytosis and polycythemia vera[8]. *Chemotherapy[7][19] ...
Pancreatic. *Pancreatitis *Acute. *Chronic. *Hereditary. *Pancreatic abscess. *Pancreatic pseudocyst. *Exocrine pancreatic ... Neoplasms and cancer. *Inflammatory bowel disease. *Gluten sensitivity. *Other. *Symptoms and signs *eponymous ...
Accessory pancreatic duct, 17. Pancreatic duct.. 18. Small intestine: 19. Duodenum, 20. Jejunum. 21-22. Right and left kidneys. ... "Solid pseudopapillary neoplasm of the pancreas: a single institution experience of 14 cases". HPB. 8 (2): 148-50. doi:10.1080/ ... Pancreatic development begins with the formation of a dorsal and ventral pancreatic bud. Each joins with the foregut through a ... A pancreatic islet that uses fluorescent antibodies to show the location of different cell types in the pancreatic islet. ...
粘液性囊性肿瘤(英语:pancreatic mucinous cystic neoplasm) ... 卵巢浆液性囊腺瘤 / Pancreatic serous cystadenoma(英语:Pancreatic serous cystadenoma) / Serous cystadenocarcinoma(英语:Serous ... Endocrine(英语:Endocrine gland neoplasm). *Prolactinoma(英语:Prolactinoma). *Multiple endocrine neoplasia(英语:Multiple endocrine ... Adnexal and skin appendage(英语:Adnexal and skin appendage neoplasms) (8390-8429). *汗
Pancreatic cancer, islet cell. *Rectal cancer. Genitourinary and gynecologic[edit]. *Bladder cancer ... Multiple myeloma/plasma cell neoplasm. *Myelodysplastic syndromes. *Mucosa-associated lymphoid tissue lymphoma ...
Some polyps are tumors (neoplasms) and others are nonneoplastic (for example, hyperplastic or dysplastic). The neoplastic ones ... Pancreatic. *Pancreatitis *Acute. *Chronic. *Hereditary. *Pancreatic abscess. *Pancreatic pseudocyst. *Exocrine pancreatic ...
Pancreas: glucagon · insulin · amylin · somatostatin · pancreatic polypeptide. Pineal gland. Pineal gland: melatonin ...
Pancreatic ductal carcinoma. *cystic neoplasms: Serous microcystic adenoma. *Intraductal papillary mucinous neoplasm ...
Neoplasms, benign or malignant. *Intussusception. *Volvulus. *Superior mesenteric artery syndrome, a compression of the ... Pancreatic. *Pancreatitis *Acute. *Chronic. *Hereditary. *Pancreatic abscess. *Pancreatic pseudocyst. *Exocrine pancreatic ...
Which pharmacologic agents are available for patients with pancreatic neuroendocrine tumors who are not candidates for surgery? ... Pancreatic neuroendocrine neoplasms (P-NENs), commonly be called pancreatic endocrine tumors, insulinoma, gastrinoma or ... Pancreatic neuroendocrine neoplasms (P-NENs) are a group of pathologically and clinically heterogeneous tumors. In the past ... The Use of Pancreatic Enzyme Replacement Therapy in Patients With a Diagnosis of Chronic Pancreatitis and Pancreatic Cancer in ...
A clinically significant pancreatic fistula was reported in 14 patients (23 per cent), and five patients (8 per cent) had a ... The most common indication for surgery was endocrine neoplasm (38 patients; 62 per cent) and two patients (3 per cent) had a ... Data collected prospectively from 61 consecutive patients who underwent pancreatic enucleation were analysed.. Results: There ... Standard resections for benign and borderline neoplasms of the pancreas are associated with a significant risk of long‐term ...
UpToDate, electronic clinical resource tool for physicians and patients that provides information on Adult Primary Care and Internal Medicine, Allergy and Immunology, Cardiovascular Medicine, Emergency Medicine, Endocrinology and Diabetes, Family Medicine, Gastroenterology and Hepatology, Hematology, Infectious Diseases, Nephrology and Hypertension, Neurology, Obstetrics, Gynecology, and Womens Health, Oncology, Pediatrics, Pulmonary, Critical Care, Sleep Medicine, Rheumatology, Surgery, and more.
Pancreatic Neoplasms. Neoplasms. Digestive System Neoplasms. Neoplasms by Site. Endocrine Gland Neoplasms. Digestive System ... EUS-guided RFA for Pancreatic Neoplasms. The safety and scientific validity of this study is the responsibility of the study ... Recently, EUS-guided RFA has become available and the device allows EUS-guided treatment of pancreatic neoplasms. The procedure ... The hypothesis is that EUS-guided RFA is safe, feasible and effective for treating solid pancreatic neoplasms. ...
Results Patients with ileal or pancreatic NENs showed increased plasma levels of total-CgA and CgA1-76 fragment (vasostatin-1, ... Conclusion These findings suggest that plasma VS-1 is a novel biomarker for ileal and pancreatic NENs. Considering that VS-1 is ... and of various CgA-derived fragments in 17 patients with ileal or pancreatic NENs, 10 healthy controls, and 21 healthy ... is a plasma biomarker widely used in the follow-up of patients with neuroendocrine neoplasms (NENs). However, its accuracy as a ...
Neoplasms. Neuroectodermal Tumors. Neoplasms, Germ Cell and Embryonal. Neoplasms by Histologic Type. Neoplasms, Nerve Tissue. ... CT Radiomic Features of Pancreatic Neuroendocrine Neoplasms. The safety and scientific validity of this study is the ... pancreatic neuroendocrine neoplasm with intervention and biopsy. *availability of pre-operatory CT scan with or without IV ... The aim of this study is to quantify inter-observer variability in delineating pancreatic neuroendocrine neoplasm (PanNEN) on ...
Prevalence, Diagnosis and Management of Pancreatic Cystic Neoplasms: Current Status and Future Directions.. Farrell JJ1. ... Prevalence, Diagnosis and Management of Pancreatic Cystic Neoplasms: Current Status and Future Directions ... BD-IPMN, branch-duct intraductal papillary mucinous neoplasm; MCN, mucinous cystic neoplasm; CT, computed tomography; MRI, ... Yale Center for Pancreatic Diseases, Interventional Endoscopy, Yale School of Medicine, New Haven, CT, USA.. ...
Specific preoperative diagnosis of pancreatic cystic neoplasms by CT alone is substantially inaccurate. Complementary tests ... Accuracy of CT in predicting malignant potential of cystic pancreatic neoplasms HPB (Oxford). 2008;10(6):483-90. doi: 10.1080/ ... Conclusion: Specific preoperative diagnosis of pancreatic cystic neoplasms by CT alone is substantially inaccurate. ... Hypothesis: The malignant potential of pancreatic cystic lesions cannot be accurately predicted by CT scan. ...
Purchase Pancreatic Neoplasms, An Issue of Surgical Oncology Clinics of North America, Volume 25-2 - 1st Edition. Print Book & ... Pancreatic Neoplasms, An Issue of Surgical Oncology Clinics of North America, Volume 25-2 1st Edition. ... Role Of EUS and ERCP In The Clinical Assessment Of Pancreatic Neoplasms; Optimal Imaging Modalities For The Diagnosis and ... is devoted to Pancreatic Neoplasms. Dr. Merchant has assembled expert authors to review the following topics: Molecular and ...
Determine Function of Antroquinonol in Combination With SOC in First Line Metastatic Pancreatic Cancer. *Pancreatic Neoplasm ... Study of CG200745 PPA in Combination With Gemcitabine and Erlotinib for Advanced Pancreatic Cancer. *Pancreatic Neoplasms ... Systemic Therapy and Chemoradiation in Advanced Localised Pancreatic Cancer - 2. *Pancreatic Neoplasms (Locally Advanced Non- ... Combination Therapy With NC-6004 and Gemcitabine Versus Gemcitabine Alone in Pancreatic Cancer. *Pancreatic Neoplasms ...
Colorectal Neoplasms · Dietary Fats · Female · Humans · Leukotrienes · Male · Neoplasms · Pancreatic Neoplasms · Prostaglandins ... esophageal neoplasms · fruit · pancreatic neoplasms · stomach neoplasms · vegetables · alcohol · alpha tocopherol · antioxidant ... Pancreatic Ducts · Pancreatic Neoplasms · Poultry · Random Allocation · Retroviridae · Retroviridae Infections · Soybeans · ... Neoplasm Proteins · Pancreatic Neoplasms · Precancerous Conditions · Proliferating Cell Nuclear Antigen · Rats · Rats, Wistar ...
GNASR201C Induces Pancreatic Cystic Neoplasms in Mice That Express Activated KRAS by Inhibiting YAP1 Signaling.. Ideno N1, ... GNASR201C Induces Pancreatic Cystic Neoplasms in Mice That Express Activated KRAS by Inhibiting YAP1 Signaling ... GNASR201C Induces Pancreatic Cystic Neoplasms in Mice That Express Activated KRAS by Inhibiting YAP1 Signaling ... GNASR201C Induces Pancreatic Cystic Neoplasms in Mice That Express Activated KRAS by Inhibiting YAP1 Signaling ...
... pancreatic intraepithelial neoplasm (PanIN) (5, 6) and intraductal papillary mucinous neoplasm (IPMN) (7, 8). These ... Trefoil factor 1 inhibits epithelial-mesenchymal transition of pancreatic intraepithelial neoplasm. Junpei Yamaguchi,1 Yukihiro ... Loss of Trefoil factor 2 from pancreatic duct glands promotes formation of intraductal papillary mucinous neoplasms in mice. ... Pancreatic duct glands (PDGs) are a progenitor compartment responsible for pancreatic ductal epithelial repair. Stem Cell Res. ...
In human samples, the expression of TFF1 was specifically observed in pancreatic intraepithelial neoplasm (PanIN), but was ... TFF1 expression was also observed in PanIN lesions of Pdx-1 Cre; LSL-KRASG12D (KC) mice, a model of pancreatic cancer, and loss ... This study indicates that the acquisition of TFF1 expression is an early event in pancreatic carcinogenesis and that TFF1 might ... To clarify the role of TFF1 in pancreatic carcinogenesis, we performed IHC on human samples, transfected siRNA against TFF1 ...
Copyright ©2018 Glenn Fleishman. Send in your comments. Bibliographic information on isbn.nu appears from various sources; read more about our data. ...
Purchase Pancreatic Cancer and Periampullary Neoplasms, An Issue of Surgical Clinics of North America, Volume 96-6 - 1st ... Pancreatic Cancer and Periampullary Neoplasms, An Issue of Surgical Clinics of North America, Volume 96-6 1st Edition. ... Pancreatic Cancer and Periampullary Neoplasms, An Issue of Surgical Clinics of North America ... Jeffrey M. Hardacre, is devoted to Pancreatic Cancer and Periampullary Neoplasms. He has assembled expert authors to review the ...
Lesion biopsy pancreatic biopsy (transendoscopic) with cytological brushings.. See also Pancreatitis - pseudocyst, abscess.. ...
Also known as: Pancreatic Neoplasm / Pancreatic Neoplasms / Tumor of pancreas / Pancreas neoplasm NOS / Pancreatic neoplasm NOS ... Neoplasms, Pancreatic Completed Phase Trials for Sufentanil (DB00708). Back to Neoplasms, Pancreatic ...
Pancreatic cancer is most lethal pancreatic disorder worldwide. *ASCO releases clinical practice guideline for pancreatic ... Pancreatic islet cell tumors, also referred to as pancreatic neuroendocrine tumors (PNETs), are incredibly rare and difficult ... but a combined review of all pancreatic lesions reported in children in the 6 known reported series of 155 total pancreatic ... If you are able to confirm that the patient has pancreatic islet cell tumors, what treatment should be initiated? ...
Pancreatic Extracts. Extracts prepared from pancreatic tissue that may contain the pancreatic enzymes or other specific ... Risk of Pancreatic Cancer in Patients with Pancreatic Cysts and Family History of Pancreatic Cancer. ... Pancreatic Neoplasms. Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various ... More From BioPortfolio on "Evaluation of Safety and Feasibility of EUS-guided RFA for Solid Pancreatic Neoplasms". *Related ...
Intraductal papillary mucinous neoplasm (IPMNs) of the pancreas may evolve from low- to high-grade dysplasia to invasive cancer ... of Plasma and Cyst Fluid Allows the Detection and Characterization of Pancreatic Intraductal Papillary Mucinous Neoplasms. 32 ... lipidomic profiles of peri-operative pancreatic cyst fluid and pre-operative fasted plasma from IPMN and serous cystic neoplasm ... Keywords: Pancreatic cancer, IPMN, Cyst fluid, Metabolomics, Lipidomics, Biomarker, Mass Spectrometry, Metabolic pathway ...
Pancreatic adenocarcinoma is the fifth most common cause of deaths from cancer in Europe, with a mortality rate close to 95%. ... Unresectable Pancreatic Neoplasms: Endoscopic and Surgical Palliation. In: Surgical Treatment of Pancreatic Diseases. Updates ... Pancreatic Cancer Celiac Plexus Endoscopic Stenting Malignant Biliary Obstruction Unresectable Pancreatic Cancer These keywords ... Potts JR 3d, Broughan TA, Hermann RE (1990) Palliative operations for pancreatic carcinoma. Am J Surg 159:72CrossRefPubMed ...
Morphine Recruiting Phase N/A Trials for Neoplasms, Pancreatic Treatment. Back to Morphine ...
Laparoscopic Versus Open Enucleation for Pancreatic Neoplasms: Clinical Outcomes and Pancreatic Function Analysis. Renchao ... This study aimed to compare perioperative outcomes of patients undergoing LE and OE and to assess the pancreatic function after ... Mortality, morbidity (30.8% vs 38.5%, P=0.733), pancreatic fistula rates (≥grade B:15.4% vs 11.5%, P=0.777)were similar between ... Background:Enucleation is an alternative procedure for treating benign or lowgrade malignant neoplasms of the pancreas. The ...
Alpha cell granules in a pancreatic neoplasm. Association with peptic ulcers. Download Prime PubMed App to iPhone, iPad, or ... Alpha cell granules in a pancreatic neoplasm. Association with peptic ulcers.. Arch Pathol. 1969 Dec; 88(6):672-6.AP ... Waisman, J. "Alpha Cell Granules in a Pancreatic Neoplasm. Association With Peptic Ulcers." Archives of Pathology, vol. 88, no ... Waisman, J. (1969). Alpha cell granules in a pancreatic neoplasm. Association with peptic ulcers. Archives of Pathology, 88(6 ...
pancreatic neuroendocrine neoplasm. Looking for others with your cancer? Want to help others? Enter info here. ... pancreatic neuroendocrine neoplasm. by Alyce » Sat Sep 20, 2008 2:37 pm ...
Pancreatic mucinous cystic neoplasm (MCN) is a type of cystic lesion that occurs in the pancreas. Amongst individuals ... Intraductal papillary mucinous neoplasm Pancreatic serous cystadenoma Elta, GH; Enestvedt, BK; Sauer, BG; Lennon, AM (April ... "Pancreatic mucinous cystic neoplasm defined by ovarian stroma: demographics, clinical features, and prevalence of cancer". ... The diagnosis of pancreatic MCN is typically achieved with imaging. If the results of imaging (CT/MRI) are unclear, then ...
... resolution MPM images clearly distinguish between the structure of normal pancreatic tissues compared with pancreatic neoplasms ... These results indicate that the MPM could potentially serve as an optical tool for the diagnosis of pancreatic neoplasms in ... Multiphoton microscopy as a diagnostic imaging modality for pancreatic neoplasms without hematoxylin and eosin stains. ... "Multiphoton microscopy as a diagnostic imaging modality for pancreatic neoplasms without hematoxylin and eosin stains," Journal ...
... neoplasms in clinical trial on Combination Therapy With NC-6004 and Gemcitabine Versus Gemcitabine Alone in Pancreatic Cancer ... Pancreatic cancer is one of the most deadly cancers because of the predominately late diagnosis. Gemcitabine (GEM) is the ... Combination Therapy With NC-6004 and Gemcitabine Versus Gemcitabine Alone in Pancreatic Cancer ... treatment of patients with locally advanced or metastatic pancreatic cancer. The main hypothesis of this study is that NC-6004 ...
Classification Classification based on function exocrine: ~99% of all primary pancreatic neoplasms pancreatic ductal ... There are numerous primary pancreatic neoplasms, in part due to the mixed endocrine and exocrine components. ... Pancreatic pathology. * pancreatic neoplasms *cystic neoplasm (cystic pancreatic mass differential diagnosis) * intraductal ... although the great majority of both benign and malignant pancreatic neoplasms arise from pancreatic epithelial cells, ...
  • Standard resections for benign and borderline neoplasms of the pancreas are associated with a significant risk of long‐term functional impairment, whereas enucleation preserves healthy parenchyma and pancreatic function. (ingentaconnect.com)
  • Cystic neoplasms of the pancreas are found with increasing prevalence, especially in elderly asymptomatic individuals. (nih.gov)
  • This review discusses the different cystic neoplasms of the pancreas and reports diagnostic strategies based on clinical features and imaging data. (nih.gov)
  • Also searched for Pancreatic cancer , PANCREATIC CARCINOMA , and Pancreas Cancer . (clinicaltrials.gov)
  • The spectrum of peptide receptors in pancreas of control and azaserine-treated rats in this study may help to understand the mechanism whereby gut hormones may modulate pancreatic carcinogenesis. (tudelft.nl)
  • Mutations at hotspots in GNAS, which encodes stimulatory G-protein, α subunits, are detected in approximately 60% of intraductal papillary mucinous neoplasms (IPMNs) of the pancreas. (nih.gov)
  • Background: Intraductal papillary mucinous neoplasm (IPMNs) of the pancreas may evolve from low- to high-grade dysplasia to invasive cancer. (ssrn.com)
  • Methods: Metabolomic and lipidomic profiles of peri-operative pancreatic cyst fluid and pre-operative fasted plasma from IPMN and serous cystic neoplasm (SCN) patients were determined single-blinded in this pancreas resection cohort (n=31). (ssrn.com)
  • Background:Enucleation is an alternative procedure for treating benign or lowgrade malignant neoplasms of the pancreas. (sages.org)
  • Pancreatic mucinous cystic neoplasm (MCN) is a type of cystic lesion that occurs in the pancreas. (wikipedia.org)
  • Moreover, quantitative assessment of the cytomorphological features visualized from MPM images showed significant differences in the nuclear-cytoplasmic ratios of pancreatic neoplasms compared with normal pancreas, as well as further distinguished pancreatic malignant tumors from benign tumors. (spiedigitallibrary.org)
  • Intraductal papillary mucinous neoplasm of the pancreas: can benign lesions be differentiated from malignant lesions with multidetector CT? (radiopaedia.org)
  • The occurrence of neuroendocrine tumors of the pancreas is rare, representing 1-5% of pancreatic cancers, and it is estimated that its incidence does not exceed 5 to one million. (enets.org)
  • Intraductal tubulopapillary neoplasms of the pancreas distinct from pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. (radiopaedia.org)
  • Imaging studies of intraductal tubulopapillary neoplasms of the pancreas: 2-tone duct sign and cork-of-wine-bottle sign as indicators of intraductal tumor growth. (radiopaedia.org)
  • A case of pancreatic heterotopy of duodenal wall, intraductal papillary mucinous tumor and intraepithelial neoplasm of pancreas, papillary carcinoma of kidney in a single patient. (biomedsearch.com)
  • Solid papillary neoplasm of the pancreas: a case report. (biomedsearch.com)
  • Solid pseudopapillary epithelial neoplasms (SPENs) of the pancreas are rare but curable tumours that have a low-grade malignant potential and occur almost exclusively in young women, with an excellent prognosis after complete resection. (ajol.info)
  • Incorrect preoperative diagnoses included hydatid cyst (3 patients), mesenteric cyst (2), pancreatic cystadenoma (2), ovarian cysts (1), islet cell tumour of the pancreas (1), and cavernous haemangioma of the liver (1). (ajol.info)
  • Journal Article] Two major types of intraductal papillary mucinous neoplasm (IPMN) of the pancreas : their distinct histological and mucin phenotypic features. (nii.ac.jp)
  • This study analyzes the clinicopathologic and radiologic characteristics of malignant serous cystic neoplasm (SCN) of the pancreas through systematic review and an institutional case report. (biomedcentral.com)
  • The malignant potential of SCNs of the pancreas should be considered in the diagnosis and management of patients with pancreatic SCNs. (biomedcentral.com)
  • classified cystic neoplasms of the pancreas into serous and mucinous types in 1978 [ 6 ], SCNs were considered as a benign disease entity without risk of malignant transformation. (biomedcentral.com)
  • Malignant neoplasms of ectopic tissue are to be coded to the site mentioned, e.g., ectopic pancreatic malignant neoplasms are coded to pancreas, unspecified ( C25.9 ). (icd10data.com)
  • Mucinous cystic pancreatic neoplasms (MCPN) are rare tumors of the pancreas which mostly occur in middle-aged females. (statpearls.com)
  • Mucinous cystic pancreatic neoplasms are mostly (93%) located in the body or tail of the pancreas. (statpearls.com)
  • An abdominal ultrasonography, a computer tomography (CT) and a gastro-duodenoscopy showed a mass of the pancreatic head with duodenal infiltration suggesting for adenocarcinoma of the pancreas. (sciepub.com)
  • The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Pancreatic Adenocarcinoma discuss the workup and management of tumors of the exocrine pancreas. (expertscape.com)
  • Pancreatic cystic neoplasms are fluid-filled sacs (cysts) within the pancreas. (letswinpc.org)
  • Adenocarcinoma of the pancreas was the most common pancreatic lesion found followed by neuroendocrine, solid pseudo papillary and Mixed neuroendocrine tumours. (seronijihou.com)
  • At the Pancreas Center, our goal is to provide comprehensive care to patients with pancreatic cancer and the precursors of the disease. (pancreasny.com)
  • Adenocarcinoma of the Pancreas: CT scanCT can confirm pancreatic cancer with a sensitivity of 85-95% (sensitivity is limited by smaller tumor size)Other than the presence of a pancreatic mass, what else can you determine from CT scan? (vdocuments.mx)
  • This appearance is very different from the more common pancreatic cancer (ductal adenocarcinoma) of the pancreas, which forms firm, sometimes rock-hard, white to yellow poorly-defined infiltrative masses. (jhu.edu)
  • Pancreatic endocrine neoplasms also differ from pancreatic cancers (ductal adenocarcinomas) of the pancreas under the microscope. (jhu.edu)
  • These tumors, although not as aggressive as pancreatic cancer (ductal adenocarcinoma of the pancreas), are nonetheless fully malignant tumors. (jhu.edu)
  • Background: von Hippel-Lindau (vHL) disease is an autosomal dominant syndrome associated with neoplasms in multiple organs, which includes the pancreas. (elsevier.com)
  • Limited oncologic resection or major surgery for cystic neoplasms of the pancreas? (cancerlink.ru)
  • Serous cystic neoplasms represent about 30% of all cystic neoplasms of the pancreas and are characterized by their microcystic appearance (on imaging, macroscopically, and microscopically) and their benign biologic behavior. (elsevier.com)
  • Mucinous cystic neoplasms (MCNs) of the pancreas represent one of the most common primary pancreatic cystic neoplasms, accounting for approximately half of these cases. (elsevier.com)
  • Classically it is described as diffuse pancreatic enlargement, which becomes featureless secondary to loss of normal pancreatic lobulations, foreshortening of the pancreatic tail and a peripheral rind or 'wrapping' around the pancreas, which appears hypodense on CT and as hypointense on both T1 and T2 images (Figure 13). (appliedradiology.com)
  • 21 On imaging, there is significant atrophy of the pancreas, marked dilatation of the pancreatic duct, and large intrapancreatic ductal stones, which have been reported up to 5 cm in size. (appliedradiology.com)
  • Pancreatic hydatid cyst masquerading as cystic neoplasm of pancreas. (bvsalud.org)
  • IPMN pathology, its risk for development into pancreatic ductal adenocarcinoma, the pros and cons of current guidelines for management, and the potential role of endoscopic ultrasound in determining cancer risk are discussed. (nih.gov)
  • Malignant neoplasms are much more common, and ductal adenocarcinoma is the most common. (ovid.com)
  • The purpose of this lesson is to review four of the most common and radiologically interesting pancreatic neoplasms: ductal adenocarcinoma, microcystic adenoma, mucinous cystic neoplasms, and islet cell neoplasms. (ovid.com)
  • In human samples, the expression of TFF1 was specifically observed in pancreatic intraepithelial neoplasm (PanIN), but was frequently lost in the invasive component of pancreatic ductal adenocarcinoma (PDAC). (jci.org)
  • KC) mice, a model of pancreatic cancer, and loss of TFF1 in these mice resulted in the expansion of PanIN lesions, an EMT phenotype in PanIN cells, and an accumulation of cancer-associated fibroblasts (CAFs), eventually resulting in the development of invasive adenocarcinoma. (jci.org)
  • Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies worldwide ( 1 ), partly because it is usually diagnosed at an advanced stage, with metastasis and extensive tumor invasion into other organs. (jci.org)
  • TFF1 expression is lost in the invasive component of pancreatic adenocarcinoma. (jci.org)
  • Since both NFPET treatment and prognosis significantly differ from that of ductal adenocarcinoma and other pancreatic malignant tumors, an accurate differential diagnosis is needed. (enets.org)
  • Intraductal papillary mucinous neoplasms (IPMN) are a distinct type of precursor lesions that cause about 5% of pancreatic adenocarcinoma ( 1, 2 ). (aacrjournals.org)
  • Combined erlotinib/gemcitabine therapy improves overall survival and progression-free survival versus gemcitabine alone in pancreatic adenocarcinoma patients ( 9 ). (aacrjournals.org)
  • Common genetic variants associated with pancreatic adenocarcinoma may also modify risk of pancreatic neuroendocrine neoplasms. (ox.ac.uk)
  • CONCLUSION: This review discusses the histopathology, genetic and epigenetic alterations and potential treatment targets of the five major malignant pancreatic tumors - pancreatic ductal adenocarcinoma, pancreatic neuroendocrine tumor, solid-pseudopapillary neoplasm, acinar cell carcinoma and pancreatoblastoma. (uu.nl)
  • Treatment and Visualization of Pancreatic Ductal Adenocarcinoma through Actively Targeted Copper 64 Nanoparticles. (ouhsc.edu)
  • Houchen CW, Li M. A subset of epithelial cells mimics regulatory T cells and contributes to immune evasion during development of pancreatic adenocarcinoma. (ouhsc.edu)
  • Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines. (expertscape.com)
  • These NCCN Guidelines Insights provide a summary and explanation of major changes to the 2012 NCCN Guidelines for Pancreatic Adenocarcinoma. (expertscape.com)
  • The Evolving Understanding of the Molecular and Therapeutic Landscape of Pancreatic Ductal Adenocarcinoma. (expertscape.com)
  • Pancreatic adenocarcinoma is the most common exocrine tumour. (seronijihou.com)
  • Most of the periampullary neoplasms were found in the duodenum with ductal adenocarcinoma being most common. (seronijihou.com)
  • For comparison pancreatic ductal adenocarcinoma (PDAC) and normal pancreatic tissues were analyzed in parallel. (elsevier.com)
  • To create a structured computed tomography (CT) report for the systematic evaluation of pancreatic ductal adenocarcinoma (PDAC), based on the opinions of clinicians and surgeons . (bvsalud.org)
  • Groove pancreatitis can occasionally mimic pancreatic adenocarcinoma given its focal nature, its propensity to cause strictures of the bile and pancreatic ducts, and its fibrotic character, which leads to decreased enhancement and T1 hypointensity. (appliedradiology.com)
  • Findings favoring groove pancreatitis over adenocarcinoma include cystic changes within the lesion, smooth rather than abrupt narrowing of the pancreatic and CBD, and a sheet-like mass rather than a rounded mass. (appliedradiology.com)
  • The differences and similarities in imaging features of focal autoimmune pancreatitis and pancreatic adenocarcinoma are listed in Table 4. (appliedradiology.com)
  • This disease is associated with a marked predisposition to pancreatic adenocarcinoma, which occurs at an early average age of 45 years. (appliedradiology.com)
  • Pancreatic neuroendocrine neoplasms (P-NENs) are a group of pathologically and clinically heterogeneous tumors. (medscape.com)
  • Neuroendocrine neoplasms (NENs) once called carcinoid tumors, endocrine tumors or neuroendocrine tumors (NETs) are a group of pathologically and clinically heterogeneous tumors. (medscape.com)
  • 2% of all pancreatic tumors. (medscape.com)
  • Consecutive patients suffering from pancreatic neuroendocrine tumors and pancreatic cancers would be recruited. (clinicaltrials.gov)
  • and Medical Management of Pancreatic Neuroendocrine Tumors: Current and Future Therapy. (elsevier.com)
  • Are you sure your patient has pancreatic islet cell tumors? (clinicaladvisor.com)
  • Pancreatic islet cell tumors, also referred to as pancreatic neuroendocrine tumors (PNETs), are incredibly rare and difficult to diagnose unless one has a high index of suspicion and an excellent understanding of the presenting symptoms. (clinicaladvisor.com)
  • Pancreatic tumors: emphasis on CT findings and pathologic classification. (radiopaedia.org)
  • Pancreatic endocrine tumors (pNETs) are rare but are among the most common neuroendocrine neoplasms of the abdomen. (enets.org)
  • The tumors considered nonfunctioning (15-32% of pancreatic neuroendocrine tumors) are not associated with any syndrome, and are usually incidental. (enets.org)
  • Non-functioning pancreatic endocrine tumors (NFPETs), better defined as non-hyperfunctioning, are characterized by the absence of clinical or biochemical evidence of hormone hypersecretion. (enets.org)
  • From the clinical standpoint, NFPETs can be either occasionally encountered or manifest clinically similar pancreatic tumors. (enets.org)
  • Gastroenteropancreatic neuroendocrine tumors (GEPNETs) are infrequent and heterogeneous neoplasms that have conditioned the lack of verified epidemiologic data. (enets.org)
  • Presents similarly to other pancreatic tumors, with signs/symptoms depending on location of the tumor. (radiopaedia.org)
  • Pancreatic Neuroendocrine Neoplasms (pNEN) are rare tumors which treatment still represent an important clinical problem, due to the paucity of medical treatments. (eur.nl)
  • We performed the histopathological re-evaluation of pancreatic neoplasms (including intraductal papillary mucinous neoplasms (IPMN), endocrine tumors, pancreatic intraepithelial neoplasia (PanIN), pancreatic cancers, et al. (nii.ac.jp)
  • For multiple neoplasms of the same site that are not contiguous, such as tumors in different quadrants of the same breast, codes for each site should be assigned. (icd10data.com)
  • The tumors frequently are confused with intraductal papillary mucinous neoplasms (IPMN). (statpearls.com)
  • Finally, another common feature is the benign nature of the ovarian mucinous cystic tumors, which rarely metastasize to other organs or involve lymph nodes akin to mucinous cystic pancreatic neoplasms. (statpearls.com)
  • These tumors are identified in 10% to 20% of resected pancreatic tumors. (statpearls.com)
  • The latter was described in 1978 by Compagno and Oertel, and the disease was distinguished from other serous cystic tumors and intraductal papillary mucinous neoplasms [6] . (statpearls.com)
  • Mucinous cystic pancreatic neoplasms are usually benign tumors and rarely metastasize [7] . (statpearls.com)
  • These tumors are divided into two distinct types which are intracapsular, if neoplastic invasion did not penetrate through the wall of the capsule, and extracapsular if extension through the capsular wall is evident and tumor extends into the surrounding pancreatic or extrapancreatic parenchyma. (statpearls.com)
  • Edil BH, Luo W, Li M. Genomic and single cell sequencing facilitate the dissection of heterogeneity of pancreatic tumors. (ouhsc.edu)
  • To date, the reported rates of complete resolution of pancreatic solid tumors range from 62% to 100% [ 15 - 18 ]. (e-ce.org)
  • Although some patients will present with premalignant pancreatic lesions (i.e., intraductal papillary mucinous neoplasms) or localized tumors amenable to curative resection, the majority of patients will unfortunately present with technically unresectable or metastatic disease. (houstonmethodist.org)
  • This review of the recent medical literature will discuss the optimal work-up and management of premalignant pancreatic lesions and the surgical management of localized, borderline resectable, and locally advanced (i.e., unresectable) pancreatic tumors. (houstonmethodist.org)
  • Background: Pancreatic neuroendocrine tumors (PNETs) are a rare subgroup of NETs with unique tumor biology, natural history, and clinical management. (journalcra.com)
  • Histopathology provides an important prognostic information about these tumors Objectives: We present here six cases of pancreatic neuroendocrine neoplasms Results: Of these 5 were non functional and 1 was functional (insulinoma). (journalcra.com)
  • The malignant potential of pancreatic cystic lesions cannot be accurately predicted by CT scan. (nih.gov)
  • Eight to 10 mo after initiation, up to 100% of virus-inoculated birds develop multiple hyperplastic and neoplastic pancreatic lesions of duct/ductular phenotype. (tudelft.nl)
  • Furthermore, the high- and low-fat diets caused a significant increase in areas of retrovirus-induced pancreatic lesions, as well as an increase in multiplicity of ductular neoplasms compared with short-term fat feeding. (tudelft.nl)
  • Safety and Efficacy of an Ablation Catheter for the Treatment of Pancreatic Premalignant Cyctic Lesions. (bioportfolio.com)
  • Our aim in this study was to compare the efficiency of 25G versus 22G needles in diagnosing solid pancreatic lesions by EUS-FNA. (bioportfolio.com)
  • Cystic pancreatic lesions: a simple imaging-based classification system for guiding management. (radiopaedia.org)
  • Objective Pancreatic cancer can arise from precursor lesions called intraductal papillary mucinous neoplasms (IPMN), which are characterised by cysts containing papillae and mucus-producing cells. (bmj.com)
  • The ductal epithelium can give rise to glandular neoplasms and papillary lesions, which probably both contribute to IPMN formation. (bmj.com)
  • Here, we identified pancreatic intraepithelial neoplasia (PanIN) lesions, the putative precursors of PC, in the ducts of pancreata resected for IPMN and assessed the frequency of molecular aberrations common to PanIN and PC, within these lesions. (garvan.org.au)
  • There were no significant differences in sensitivity for discriminating PCNs from pancreatic cystic lesions between CEUS and MRI (p=0.614) or between CEUS and CT (p=0.479). (oncologynurseadvisor.com)
  • High-quality cross-sectional imaging examinations and medical checkups have significantly increased the detection of pancreatic cystic lesions (PCLs). (oncologynurseadvisor.com)
  • Conclusions: Measurement of protein glycosylation profiles in serum may aid in the early detection of pancreatic cancer and precursor lesions. (lu.se)
  • These shared characteristics include the mucinous secreting columnar epithelium and the surrounding ovarian stroma that are seen in both ovarian and pancreatic mucinous cystic lesions. (statpearls.com)
  • Invasive mucinous cystic pancreatic neoplasm usually presents in elderly patients, and the difference in average age between benign and malignant disease of 11 years alludes to the fact that benign lesions can be precancerous. (statpearls.com)
  • These cystic lesions, as opposed to intraductal papillary mucinous neoplasms, do not connect with pancreatic ducts, and this is often a distinguishing characteristic. (statpearls.com)
  • Conversely, most mucinous cystic pancreatic neoplasms lesions are benign and rarely metastasizes to lymph nodes or other organs. (statpearls.com)
  • It is believed that benign lesions can transform into malignant mucinous cystic pancreatic neoplasms due to the older age of presentation in patients with invasive cancer [8] . (statpearls.com)
  • Conservative treatment is a reasonable option in selected patients (for example in the presence of small, asymptomatic lesions in the pancreatic head, especially in the frail or elderly patient). (elsevier.com)
  • Increased utilization of cross-sectional imaging, such as MDCT and MR, has led to an increased detection of cystic pancreatic lesions with nearly a third of cases being diagnosed in asymptomatic patients (Tables 5 and 6) and a prevalence of incidental cystic lesions on CT being present in 2.6% of examinations. (appliedradiology.com)
  • 22 Despite the significant overlap in the imaging features of pancreatic cystic lesions, MDCT andMRI are fairly accurate in the characterization of these lesions. (appliedradiology.com)
  • Interpretation: An integrated metabolomic and lipidomic analysis of plasma or cyst fluid can improve discrimination of IPMN from SCN and within PMNs predict the grade of dysplasia, which is highly relevant for pancreatic surgery management. (ssrn.com)
  • Histologically, these tumours are distinct from pancreatic intraepithelial neoplasia, intraductal papillary mucinous neoplasm (IPMN) , and intraductal variant of pancreatic acinar cell carcinoma . (radiopaedia.org)
  • Like a main-duct IPMN, an ITPN demonstrates a dilated and irregular main pancreatic duct, but without an abundance of low attenuation mucin. (radiopaedia.org)
  • The high frequency of KRAS mutations in IPMN and histological analyses suggest that oncogenic KRAS drives IPMN development from pancreatic duct cells. (bmj.com)
  • Here we explore whether combining oncogenic Kras G12D mutation with an additional gene mutation known to occur in human IPMN can induce IPMN from pancreatic duct cells. (bmj.com)
  • Time course analysis suggested that IPMN developed from intraductal papillae and glandular neoplasms, which both derived from the epithelium lining large pancreatic ducts. (bmj.com)
  • β-catenin was required for the development of glandular neoplasms and subsequent development of the mucinous cells in IPMN. (bmj.com)
  • The development of pancreatic cancer (PC) several years after curative resection for noninvasive intraductal papillary mucinous neoplasm (IPMN) and the presence of PC distant from IPMN suggest that PC may develop independently of the IPMN. (garvan.org.au)
  • Here we show that the tumor antigen MUC1, which is abnormally expressed on pancreatic cancer and is a target for cancer immunosurveillance, is also abnormally expressed on premalignant IPMN. (physiciansweekly.com)
  • Here, we performed high-throughput screening and targeted verification of glycome alterations in serum samples from patients with pancreatic cancer and the precancerous lesion intraductal papillary mucinous neoplasm (IPMN). (lu.se)
  • The top 10 glycoprotein biomarker candidates with the highest signal intensity difference in glycosylation levels were evaluated in a cohort consisting of 109 serum samples, including 49 patients with resectable pancreatic cancer, 13 patients with resectable noninvasive IPMN and 47 healthy controls, using a targeted assay. (lu.se)
  • Results: Multivariable analysis defined sets of panels comprising CA19-9 and distinctively glycosylated proteins for discrimination between pancreatic cancer, IPMN and healthy controls. (lu.se)
  • In IPMN cases, slightly high villous architecture and nuclear overlapping were the most important findings to differentiate among intraductal papillary mucinous adenoma (IPMA), intraductal papillary mucinous neoplasm, borderline (IPMB), and intraductal papillary mucinous carcinoma (IPMC). (nii.ac.jp)
  • Secondary outcomes included safety in IPMN patients and pharmacokinetics in pancreatic tissue. (aacrjournals.org)
  • Even when diagnoses were dichotomized as benign (43%) or potentially malignant (57%, papillary mucinous neoplasms, mucinous cystic neoplasms, cancer), determinations based on CT alone were accurate in an average of 61% of cases. (nih.gov)
  • Department of Translational Molecular Pathology, Sheikh Ahmed Center for Pancreatic Cancer Center, Houston, Texas. (nih.gov)
  • To clarify the role of TFF1 in pancreatic carcinogenesis, we performed IHC on human samples, transfected siRNA against TFF1 into pancreatic cancer cell lines, and employed mouse models in which PanIN development and loss of TFF1 occur simultaneously. (jci.org)
  • When the expression of TFF1 was suppressed in vitro, pancreatic cancer cell lines showed enhanced invasive ability and features of epithelial-mesenchymal transition (EMT), including upregulated Snail expression. (jci.org)
  • This issue of Surgical Clinics of North America, guest edited by Dr. Jeffrey M. Hardacre, is devoted to Pancreatic Cancer and Periampullary Neoplasms. (elsevier.com)
  • The aim of this study is to evaluate if the early change of needle during EUS-FNA for suspected pancreatic cancer allows an earlier preliminary cytological diagnosis of neoplasia. (bioportfolio.com)
  • This is a clinical trial to compare two needles used in biopsy techniques to acquire tissue from pancreatic cancer. (bioportfolio.com)
  • Preoperative EUS-guided fine-needle aspiration: effects on peritoneal recurrence and survival in patients with pancreatic cancer. (bioportfolio.com)
  • Endoscopic ultrasound-guided fine-needle aspiration (EUS-guided FNA) is an accurate and relatively safe tissue confirmation method for pancreatic cancer. (bioportfolio.com)
  • Risk of Pancreatic Cancer in Patients with Pancreatic Cysts and Family History of Pancreatic Cancer. (bioportfolio.com)
  • A diagnosis of pancreatic cancer in a first-degree relative increases an individuals' risk of this cancer. (bioportfolio.com)
  • However, it is not clear whether this cancer risk increases in individuals with pancreatic cy. (bioportfolio.com)
  • Pancreatic carcinoma is a common cause of cancer deaths worldwide. (bioportfolio.com)
  • Pancreatic cancer: a symptomless killer. (bioportfolio.com)
  • Pancreatic cancer is the fifth most common cause of cancer death in the UK. (bioportfolio.com)
  • Richard K, Muhammad WS (2007) Is there an optimal neoadjuvant therapy for locally advanced pancreatic cancer? (springer.com)
  • Singh SM, Longmire WP Jr, Reber HA et al (1990): Surgical palliation for pancreatic cancer. (springer.com)
  • deRooij PD, Rogatko A, Brennan MF (1991) Evaluation of palliative surgical procedures in unresectable pancreatic cancer. (springer.com)
  • Watanapa P, Williamson RC (1992) Surgical palliation for pancreatic cancer: developments during the past two decades. (springer.com)
  • Urbach DR, Bell CM, Swanstrom LL et al (2003) Cohort study of surgical bypass to the gallbladder or bile duct for the palliation of jaundice due to pancreatic cancer. (springer.com)
  • House MG, Choti MA (2005) Palliative therapy for pancreatic/biliary cancer. (springer.com)
  • Lillemoe KD, Cameron JL, Yeo CJ et al (1996) Pancreaticoduodenectomy: does it have a role in the palliation of pancreatic cancer? (springer.com)
  • Lillemoe KD, Cameron JL, Kaufman HS et al (1993) Chemical splanchnicectomy in patients with unresectable pancreatic cancer. (springer.com)
  • However, cyst fluid analysis cannot rule out the presence of pancreatic cancer or high grade dysplasia. (wikipedia.org)
  • The purpose of this study was to further expand the versatility of MPM by establishing the optical parameters required for imaging unstained histological sections of pancreatic neoplasms, thereby providing an efficient and environmentally sustainable alternative to H&E staining while improving the accuracy of pancreatic cancer diagnoses. (spiedigitallibrary.org)
  • This clinical trial is designed to evaluate the impact of the addition of NC-6004 to gemcitabine in the treatment of patients with locally advanced or metastatic pancreatic cancer in Asian countires. (centerwatch.com)
  • Pancreatic cancer is one of the most deadly cancers because of the predominately late diagnosis. (centerwatch.com)
  • Gemcitabine (GEM) is the standard treatment for advanced and metastatic pancreatic cancer. (centerwatch.com)
  • According to preclinical data and few early phase studies, a combined use of gemcitabine and cisplatin (CDDP) showed synergistic efficacy against pancreatic cancer. (centerwatch.com)
  • A possible explanation for the relationship of diabetes mellitus and liver cancer is provided by our previous studies in an animal model of hormonally induced hepatocarcinogenesis in which intrahepatic low number (i.e., 350-450 islets) pancreatic islet transplantation in streptozotocin-diabetic Lewis rats seemed to be the primary trigger for carcinogenesis ( 19 - 26 ). (aacrjournals.org)
  • Exocrine pancreatic and enterocyte function in patients with advanced pancreatic cancer. (annals.org)
  • We report a case of the contemporaneous presence of two histologically different pancreatic neoplasms, one renal cancer and one embryogenic duodenal anomaly in a single patient. (biomedsearch.com)
  • Intraductal papillary mucinous neoplasms (IPMNs) are premalignant pancreatic cysts of which a subset has the potential to progress to cancer. (physiciansweekly.com)
  • Material and methods: The glycosylation profile of 1000 proteins was mapped in a discovery cohort comprising serum samples from 16 individuals, including 8 patients with pancreatic cancer and 8 healthy controls. (lu.se)
  • A panel including CA 19-9, IL.17E, B7.1 and DR6 gave an AUC of 0.988 at 100% sensitivity at 90% specificity for the discrimination of stage 1 pancreatic cancer and healthy controls. (lu.se)
  • Chronic pancreatitis can present as a focal inflammatory mass mimicking pancreatic neoplasm and also it has increased risk of developing pancreatic cancer. (jcdr.net)
  • Mizuno S, Kato H, Yamaue H, Fujii T, Satoi S, Saiura A, Murakami Y, Sho M, Yamamoto M, Isaji S. Left-sided Portal Hypertension After Pancreaticoduodenectomy With Resection of the Portal Vein/Superior Mesenteric Vein Confluence in Patients With Pancreatic Cancer: A Project Study by the Japanese Society of Hepato-Biliary-Pancreatic Surgery. (ucdenver.edu)
  • Rangelova E, Wefer A, Persson S, Valente R, Tanaka K, Orsini N, Segersvärd R, Arnelo U, Del Chiaro M. Surgery Improves Survival After Neoadjuvant Therapy for Borderline and Locally Advanced Pancreatic Cancer: A Single Institution Experience. (ucdenver.edu)
  • CD40 Agonist Overcomes T Cell Exhaustion Induced by Chronic Myeloid Cell IL-27 Production in a Pancreatic Cancer Preclinical Model. (ucdenver.edu)
  • Using homology to the rat mta1 gene, we cloned the human MTA1 gene and found it to be over-expressed in a variety of human cell lines (breast, ovarian, lung, gastric and colorectal cancer but not melanoma or sarcoma) and cancerous tissues (breast, esophageal, colorectal, gastric and pancreatic cancer). (readbyqxmd.com)
  • A benign mucinous cystic pancreatic neoplasm can potentially evolve into an aggressive cancer, and hence, surgical resection is recommended in younger patients [2] . (statpearls.com)
  • Yang Y, Ding L, Cao Z, Qu D, Weygant N. Tuft cells: an emerging therapeutic target for pancreatitis and pancreatic cancer? (ouhsc.edu)
  • Tuft Cells Play Critical Roles in the Heterogeneity and Epithelial Plasticity in Pancreatic Cancer Initiation and Progression. (ouhsc.edu)
  • Patient-derived Organoid Pharmacotyping is a Clinically Tractable Strategy for Precision Medicine in Pancreatic Cancer. (ouhsc.edu)
  • Pancreatic oncology focuses on the management and treatment of pancreatic cancer through chemotherapy, radiation, surgery, and targeted cancer therapy. (healthgrades.com)
  • Pancreatic cancer is the third leading cause of cancer-related deaths, characterised by poor survival, marked molecular heterogeneity and high intrinsic and acquired chemoresistance. (expertscape.com)
  • Only 10⁻20% of pancreatic cancer patients present with surgically resectable disease and even then, 80% die within 5 years. (expertscape.com)
  • Understanding the Pathophysiology of Psychological Distress and Pancreatic Cancer: A Systematic Review. (expertscape.com)
  • BACKGROUND: Psychological distress is highly prevalent in patients with pancreatic cancer (PC), yet little is known about the pathophysiology underlying the relationship between these 2 diseases. (expertscape.com)
  • Pancreatic Cancer is an online community for sharing information about innovative, science-based treatments for pancreatic cancer. (letswinpc.org)
  • Pancreatic cancer is lethal malignancy it is a seventh leading cause of cancer death in the world. (seronijihou.com)
  • Pancreatic cancer affects patients in their late adult life with a peak in the sixth - eight decade of life with male predominance. (seronijihou.com)
  • Pancreatic cancer is a complex disease that requires expert care from multiple providers in several specialties to achieve a maximal outcome for each individual patient. (pancreasny.com)
  • For those patients who come to us with a diagnosis of pancreatic cancer we aim to offer the best possible care at every stage of the disease. (pancreasny.com)
  • For patients who present with "inoperable' pancreatic cancer, we have an aggressive protocol that will lead to surgical removal of the tumor in a majority of patients. (pancreasny.com)
  • Finally, our center is committed to being part of the strong network of advocacy groups to promote awareness and funding for pancreatic cancer. (pancreasny.com)
  • Pancreatic Cancer: Serum MarkersIs there a role for serum markers? (vdocuments.mx)
  • Pancreatic cancer is the fourth leading cause of cancer deaths in the USA. (houstonmethodist.org)
  • They also discuss Neoplasm Pancreatic Cancer. (fyntv.net)
  • Why is it so hard to diagnose Pancreatic Cancer? (fyntv.net)
  • Risk/benefit of total pancreatectomy for pancreatic cancer: are there indications? (cancerlink.ru)
  • Who benefits from ultraradical pancreatic cancer resection? (cancerlink.ru)
  • Neoadjuvant chemotherapy and radiochemotherapy: is there a survival advantage for pancreatic cancer patients? (cancerlink.ru)
  • The clinical presentation is similar to pancreatic cancer, with weight loss and obstructive jaundice, but presents with the absence of severe attacks of abdominal pain seen with acute pancreatitis. (appliedradiology.com)
  • Elevation of IgG4is rare in pancreatic cancer and is observed only in 10% of cases. (appliedradiology.com)
  • Amongst individuals undergoing surgical resection of a pancreatic cyst, about 23 percent were mucinous cystic neoplasms. (wikipedia.org)
  • Where possible, surgical resection of mucinous cystic neoplasms is preferable. (wikipedia.org)
  • Ethanol and paclitaxel ablation of pancreatic cysts may be a viable alternative to surgical resection. (clinicaltrials.gov)
  • Experimental Design: Pancreatic cyst fluid samples from 183 patients (29 discovery, 154 validation) aspirated after surgical resection were analyzed for methylated DNA at selected genes (SOX17, BNIP3, FOXE1, PTCHD2, SLIT2, EYA4 and SFRP1) using methylation-specific droplet-digital PCR (dd-QMSP). (aacrjournals.org)
  • Postoperative complications included a stricture at the hepaticojejunostomy after pancreaticoduodenectomy, which resolved after stenting, and a pancreatic duct fistula after local tumour resection, which required a distal pancreatectomy. (ajol.info)
  • Despite the indolent biological behaviour of SPENs, most patients required major pancreatic resection. (ajol.info)
  • Background: Peptide receptor radionuclide therapy (PRRT) can be an option for advanced pancreatic neuroendocrine neoplasms (PNENs) to allow patients undergo resection. (endocrine-abstracts.org)
  • Results: Overall, 20 patients underwent sequential PRRT and pancreatic resection. (endocrine-abstracts.org)
  • Conclusions: Pancreatic resection for PNEN after neoadjuvant PRRT is safe and associated with a lower risk of developing pancreatic fistula. (endocrine-abstracts.org)
  • Although surgical resection is the definitive treatment for pancreatic neoplasms with malignant transformation potential, it carries relatively high risks of perioperative morbidity and mortality [ 4 ]. (e-ce.org)
  • Dr. Porubcin has more experience with Pancreatic Neoplasms, Renal Neoplasms & Resection, and Skeletal System Neoplasms than other specialists in his area. (healthgrades.com)
  • Compare with other Renal Neoplasms & Resection specialists. (healthgrades.com)
  • This study indicates that the acquisition of TFF1 expression is an early event in pancreatic carcinogenesis and that TFF1 might act as a tumor suppressor to prevent EMT and the invasive transformation of PanIN. (jci.org)
  • It is of great importance to detect PDAC in its early stage and to understand the mechanisms by which pancreatic tumor cells obtain the ability to invade and metastasize. (jci.org)
  • Loss of ATRX or DAXX is common in well-differentiated pancreatic neuroendocrine neoplasms, and is correlated with higher tumor stage and shorter survival time. (enets.org)
  • Circulating tumor cells are captured to predict the prognosis of patients in many types of cancers, but reports are rare on clinical utility and tumor cell shedding in neuroendocrine neoplasms (NENs). (enets.org)
  • therefore, PDAC susceptibility variants (n = 23) from Caucasian genome-wide association studies (GWAS) were genotyped in 369 pNEN cases and 3277 controls from the PANcreatic Disease ReseArch (PANDoRA) consortium to evaluate the odds associated with pNEN risk, disease onset and tumor characteristics. (ox.ac.uk)
  • DCLK1-Isoform2 Alternative Splice Variant Promotes Pancreatic Tumor Immunosuppressive M2-Macrophage Polarization. (ouhsc.edu)
  • Most pancreatic endocrine neoplasms are non-syndromic, that is they do not produce a clinical syndrome caused by excess hormone production by the tumor. (jhu.edu)
  • My tumor was diagnosed as an endocrine neoplasm. (jhu.edu)
  • What is the place of interventional endoscopic treatment in chronic pancreatitis with inflammatory tumor of the pancreatic head? (cancerlink.ru)
  • 4 cm (because these 'large' neoplasms have a more rapid growth rate and probably will soon become symptomatic), and any uncertainty about the diagnosis of a serous versus a mucinous cystic neoplasm. (elsevier.com)
  • Although the overall risk of malignancy is very low, the presence of these pancreatic cysts is associated with a large degree of anxiety and further medical investigation due to concerns about malignancy. (nih.gov)
  • Finally, surgical treatment, strategies for surveillance of pancreatic cysts, and possible future directions are discussed. (nih.gov)
  • Pancreatic cysts are becoming diagnosed more frequently due to the increased use and sensitivity of imaging. (clinicaltrials.gov)
  • Our hypothesis is that ethanol with paclitaxel ablation is a safe and effective method for treatment in those with per-cancerous, mucinous pancreatic cysts. (clinicaltrials.gov)
  • Purpose: Pancreatic cysts are common and pose diagnostic and management challenges. (aacrjournals.org)
  • Pancreatic cyst fluid markers have the potential to aid in the management of cysts with concerning imaging findings. (aacrjournals.org)
  • Our aim was to evaluate cyst fluid methylated DNA markers for their accuracy for predicting the histologic grade of neoplastic pancreatic cysts. (aacrjournals.org)
  • Conclusion: A panel of methylated gene markers quantified by dd-QMSP can be used to predict the grade of dysplasia of pancreatic cysts. (aacrjournals.org)
  • 3 PCLs commonly encountered in clinical practice include pancreatic cystic neoplasms (PCNs) and nonneoplasms, which mainly refer to true cysts and pseudocysts. (oncologynurseadvisor.com)
  • A Patient Page on types of pancreatic cysts was published in the September 20, 2016, issue of JAMA . (letswinpc.org)
  • Pancreatic cysts are usually found when patients undergo abdominal imaging for other reasons. (letswinpc.org)
  • Potts JR 3d, Broughan TA, Hermann RE (1990) Palliative operations for pancreatic carcinoma. (springer.com)
  • Histopathologic analysis of the surgical specimen revealed mild differentiated papillary renal carcinoma, intraductal papillary mucinous adenoma of the pancreatic head, foci of intraepithelial pancreatic neoplasm and pancreatic heterotopy of duodenal muscular and submucosal layers. (biomedsearch.com)
  • Mucinous cystic pancreatic neoplasms with invasive carcinoma typically have malignant neoplastic cells beyond the epithelial lining of the cyst. (statpearls.com)
  • Yamaguchi K, Tanaka M. Groove pancreatitis masquerading as pancreatic carcinoma. (sciepub.com)
  • Periampullary tumours are neoplasms that arise in this site can originate from the duodenum, distal common bile duct (CBD), or the structures of the ampullary complex. (seronijihou.com)
  • Finally, surgery plays a key role in the treatment of these neoplasms. (clinicaladvisor.com)
  • Endoscopic ultrasonography (EUS)-guided therapy with ethanol injection or catheter-based radiofrequency ablation for pancreatic neoplasm has been conducted as a potential alternate treatment modality for patients who are not eligible for surgery. (e-ce.org)
  • Over the last decade, endoscopic ultrasonography (EUS)-guided ablation of pancreatic neoplasms has been performed as an experimental treatment modality for patients who were either poor surgical candidates or reluctant to undergo surgery [ 5 , 6 ]. (e-ce.org)
  • A recent retrospective study that compared patients who received EUS-guided ethanol injection for the ablation of cystic neoplasms with those who did not revealed that the patients treated with EUS-guided ablation with ethanol injection maintained their quality of life by avoiding pancreatic surgery [ 7 ]. (e-ce.org)
  • The work The Surgery of pancreatic neoplasms represents a distinct intellectual or artistic creation found in University of Manitoba Libraries . (umanitoba.ca)
  • His surgical focus is on hepatobiliary, colorectal, and pancreatic surgery and transplant surgery. (wikipedia.org)
  • Lesion biopsy pancreatic biopsy (transendoscopic) with cytological brushings. (edu.au)
  • This study aims to evaluate the safety and efficacy of new ablation catheter developed by MEDICAL TAEWOONG for the treatment of pancreatic premalignant and early malignant cystic lesion. (bioportfolio.com)
  • 1.0T MR-guided percutaneous coaxial cutting needle biopsy in pancreatic lesion diagnosis. (bioportfolio.com)
  • Computed tomography confirmed the renal lesion, but also a heterogeneous mass within the pancreatic head appeared without bile ducts dilatation. (biomedsearch.com)
  • A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion'), unless the combination is specifically indexed elsewhere. (icd10data.com)
  • Cross-sectional imaging is of key importance for the diagnostic evaluation of patients with a cystic pancreatic lesion. (elsevier.com)
  • A clinically significant pancreatic fistula was reported in 14 patients (23 per cent), and five patients (8 per cent) had a further operation for fistula‐related complications. (ingentaconnect.com)
  • Mortality, morbidity (30.8% vs 38.5%, P=0.733), pancreatic fistula rates (≥grade B:15.4% vs 11.5%, P=0.777)were similar between the two groups. (sages.org)
  • Patients who underwent neoadjuvant PRRT had a lower risk of developing pancreatic fistula (25% versus 65%, P =0.011) although the rate of overall complications was similar (45% vs 60%, P =0.342). (endocrine-abstracts.org)
  • The purpose of our study was to evaluate the role of contrast-enhanced ultrasound (CEUS) with magnetic resonance imaging (MRI) and computed tomography (CT) in the pathological diagnosis of pancreatic cystic neoplasms (PCNs). (oncologynurseadvisor.com)
  • Imaging with multidetector computed tomography (MDCT) and magnetic resonance imaging (MRI) along with the use of 3-dimensional(3D) imaging play a critical role in the evaluation of pancreatic diseases. (appliedradiology.com)
  • of tumorigenic pathways have deepened our understanding of the underlying biology of pancreatic neoplasia. (uu.nl)
  • On the other hand, in cases of pancreatic cancers, most cases revealed positive staining of p53 and MIB-1, and the nuclear atypia was obvious in such cases. (nii.ac.jp)
  • He is co-author of more than 2,500 scientific publications focused on gastrointestinal cancers, pancreatic diseases and clinical surgical issues. (wikipedia.org)
  • The five-year disease-specific survival for benign and malignant mucinous cystic pancreatic neoplasms is 100% and 57%, respectively. (statpearls.com)
  • Of the reported cases of pancreatic islet cell neoplasm associated with gastric hypersecretion (Zollinger-Ellison syndrome), about one-third include diarrhea as a prominent symptom. (annals.org)
  • A total of 22 patients with pancreatic neoruendocrine neoplasms with liver metastases underwent hepatectomy in our center from June 2005 to April 2015. (enets.org)
  • In 1 patient, 2 liver metastases were resected in addition to the pancreatic primary tumour. (ajol.info)
  • ASGE Standards of Practice Committee 2016, ' The role of endoscopy in the diagnosis and treatment of cystic pancreatic neoplasms ', Gastrointestinal endoscopy , vol. 84, no. 1, pp. 1-9. (elsevier.com)
  • To prospectively evaluate the diagnostic value of preoperative histological subtyping of intraductal papillary mucinous neoplasms (IPMNs) by pancreatic juice cytology (PJC) with mucin (MUC) stain. (unboundmedicine.com)
  • Immunobiology and immunosurveillance in patients with intraductal papillary mucinous neoplasms (IPMNs), premalignant precursors of pancreatic adenocarcinomas. (physiciansweekly.com)
  • 4,5 The most common PCNs consist of serous cystadenomas (SCAs), mucinous cystadenomas (MCAs), intraductal papillary mucinous neoplasms (IPMNs), and solid pseudopapillary neoplasms (SPNs). (oncologynurseadvisor.com)
  • Autoimmune pancreatitis, first described in 1995, is pathologically characterized by dense inflammatory infiltrates of lymphocytes and plasma cells around the small- to medium-sized pancreatic ducts with associated fibrosis. (appliedradiology.com)
  • This issue of Surgical Oncology Clinics of North America, guest edited by Nipun Merchant, MD, is devoted to Pancreatic Neoplasms. (elsevier.com)
  • Surgical Management of Pancreatic Neoplasms: What's New? (houstonmethodist.org)
  • Fingerprint Dive into the research topics of 'Surgical Management of Pancreatic Neoplasms: What's New? (houstonmethodist.org)
  • Primary pancreatic cystic neoplasms revisited. (elsevier.com)
  • Fingerprint Dive into the research topics of 'Primary pancreatic cystic neoplasms revisited: Part II. (elsevier.com)
  • The aim of this study is to quantify inter-observer variability in delineating pancreatic neuroendocrine neoplasm (PanNEN) on Computerized Tomography (CT) images and its impact on radiomic features (RF), subsequently to this determination, to use CT texture analysis to predict, histological characteristics of PanNEN on CT scans. (clinicaltrials.gov)
  • [ 26-31 ] Therefore, in 2017, the new WHO classification introduced a new category of well-differentiated pancreatic NETs (WD-pNETs) G3, different from poorly differentiated pancreatic NECs (PD-pNECs) G3. (medscape.com)
  • Here, we report the greatest single center experience in patients with vHL pancreatic endocrine neoplasm (PNETs). (elsevier.com)
  • The effects of vitamins E and E, β-carotene and selenium on development of N-nitrosobis(2-oxopropyl)amine (BOP)-induced pancreatic tumours in hamsters were investigated. (tudelft.nl)
  • This study was carried out to determine the histopathological pattern of the pancreatic tumours in the various age group thorough histopathological evaluation and immunohistochemically studies along with clinical correlation will ease the burden of Pancreatic disease. (seronijihou.com)
  • Mallery, JS & Gupta, K 2009, Diagnosis and Staging of Solid Pancreatic Neoplasms . (umn.edu)
  • Endoscopic ultrasound-guided fine-needle aspiration biopsy (EUS-FNA) is a reliable, safe, and effective technique for obtaining samples from pancreatic masses. (bioportfolio.com)
  • Endoscopic ultrasound will be used to locate and assess the pancreatic cyst. (clinicaltrials.gov)
  • Introduction: For pathological diagnosis of pancreatic neuroendocrine neoplasms (pNENs) the routinely used immunohistochemical markers are chromogranin A (CgA) and synaptophysin (Syn). (elsevier.com)
  • We found that the high-resolution MPM images clearly distinguish between the structure of normal pancreatic tissues compared with pancreatic neoplasms in unstained histological sections, and discernable differences in tissue architecture and cell morphology between normal versus tumorigenic cells led to enhanced optical diagnosis of cancerous tissue. (spiedigitallibrary.org)
  • Results: Actn-4sv was expressed in 88.5% (108/122) of pNENs, but not in normal pancreatic tissues (0/14) or PDAC (0/14). (elsevier.com)
  • However, the incidence, multiplicity, and areas of the pancreatic tissue occupied by intra- and interlobular aggregates of hyperplastic ducts with mucinous metaplasia of the lining cells were significantly increased compared with the birds fed the common diet. (tudelft.nl)
  • Extracts prepared from pancreatic tissue that may contain the pancreatic enzymes or other specific uncharacterized factors or proteins with specific activities. (bioportfolio.com)
  • However, whether erlotinib and its active metabolite achieve therapeutic levels in pancreatic tissue has never been evaluated. (aacrjournals.org)
  • Resected pancreatic tissue was also used to quantify pharmacokinetics of erlotinib and OSI-420, its major active metabolite, which had not previously been performed. (aacrjournals.org)
  • Pharmacokinetics of pancreatic erlotinib were performed in 4 participants (Supplementary Table S2) Concentrations were determined in matched plasma and pancreatic tissue by HPLC-MS/MS (high-performance liquid chromatography-mass spectrometry) as previously described ( 14 ). (aacrjournals.org)
  • The inflammatory involvement results in scar-tissue formation in the pancreatico-duodenal groove and subsequent cystic dystrophy of heterotopic pancreatic tissue in the duodenal wall. (appliedradiology.com)
  • Pancreatic ductal adenocarcinomas (PDACs) were isolated from mice and used to generate cell lines, which were analyzed by reverse transcription polymerase chain reaction, immunoblotting, immunohistochemistry, and colony formation and invasion assays. (nih.gov)
  • The survival rate for this disease is far better than pancreatic ductal adenocarcinomas. (statpearls.com)
  • This is believed to be the case because ovarian mucinous cystic neoplasms share the same histology and characteristics as mucinous cystic pancreatic neoplasms. (statpearls.com)
  • Primary pancreatic cystic neoplasms have been recognized increasingly during the two recent decades and include mainly serous cystic neoplasms, mucinous cystic neoplasms, and intraductal papillary mucinous neoplasms. (elsevier.com)
  • Objective: Because histologic features can be unreliable in determining the malignant potential of pancreatic endocrine neoplasms (PENs), we characterized the methylation patterns of PENs to develop a molecular marker system useful for clinical prognosis. (elsevier.com)
  • Prevalence, Diagnosis and Management of Pancreatic Cystic Neoplasms: Current Status and Future Directions. (nih.gov)
  • Chromogranin A (CgA) is a plasma biomarker widely used in the follow-up of patients with neuroendocrine neoplasms (NENs). (plos.org)
  • In the attempt to identify a more reliable biomarker for NENs, we investigated, by ELISA, the circulating levels of full-length CgA (CgA 1-439 ) and of various CgA-derived fragments in 17 patients with ileal or pancreatic NENs, 10 healthy controls, and 21 healthy volunteers before and after treatment with PPIs. (plos.org)
  • These findings suggest that plasma VS-1 is a novel biomarker for ileal and pancreatic NENs. (plos.org)
  • Human Chromogranin A (CgA), a 439-residue-long protein present in the secretory granules of many normal and neoplastic neuroendocrine cells, currently represents the main biomarker for neuroendocrine neoplasms (NENs) [ 1 , 2 ]. (plos.org)
  • 6,7 Neuroendocrine neoplasms (NENs) and cystadenocarcinomas are relatively less common PCNs. (oncologynurseadvisor.com)